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Chapter 1 
OBJECTIVES OF THE THESIS 
Neural-tube defects (NTDs) are the most widely prevalent of all birth defects 
(EUROCAT Working Group 1991 ). They range from meningo(myelo)cele to anen-
cephaly and may be diagnosed during the antenatal period or at birth as well as in 
spontaneous abortion products (Byrne and Warburton, 1986). These birth defects 
account for a significant part of todays perinatal morbidity and mortality. Therefore, 
if measures are taken to prevent the development of NTDs, an improvement in peri-
natal outcome may result. 
Before the primary prevention of NTDs can become a reality, it is necessary to 
gain a clear understanding of the teratogens and risk factors involved in their aetiol-
ogy. The development of the neural-tube in the human fetus takes place during the 
3rd and 4th week after conception. Therefore, any preventive measures should be 
taken in the preconceptional period until at least the 4th postconceptional week. 
During the past three decades vitamin levels, in particular that of folate, have 
repeatedly been considered to have a significant impact on pregnancy outcome, 
such as NTDs, recurrent spontaneous abortion and abruptio placentae (Hibbard 
1964; Smithells et al., 1976; Schorah et al., 1980). Furthermore, periconceptional 
folate treatment of the mother has recently been demonstrated to reduce the recur-
rence and possibly the first occurrence frequency of NTDs (Medical Research 
Council (MRC) Vitamin Study Research Group 1991; Czeizel and Dudas, 1992). 
The precise pathogenesis by which a relative or absolute shortage of folate causes 
NTDs, recurrent spontaneous abortion or abruptio placentae, as well as the mechan-
ism through which folate therapy may prevent these specific obstetric sequelae are, 
however, still unclear. 
Folate is essential for deoxyribonucleic acid (DNA) and transfer-ribonucleic acid 
(tRNA) synthesis as well as for amino acid metabolism and, consequently, it is 
essential to cell division (Rosenblatt 1989). Folate is of particular importance in the 
metabolism of the essential amino acid methionine (Finkelstein 1990). An insuffi-
cient availability of folate, due to an acquired, i.e., nutritional, or inherited derange-
ment of folate metabolism, can lead to a disturbance in the remethylation of homo-
cysteine to methionine. This, in tum, can result in elevated blood concentrations of 
homocysteine, viz. hyperhomocysteinaemia. 
The suggested beneficial effect of vitamin treatment, in particular that of folate, 
in the prevention of these obstetric problems might be explained by an attenuation 
of this metabolic disturbance and subsequent decrease of homocysteine concentra-
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tions in blood, as has been shown in classic homocystinuna (Boers et al , 1983a 
Brattstrom et al , 1990) 
The teratogenicity of homocysteine in homozygotes for homocystinuna is large-
ly unknown Mudd et al (1985) reported a fetal loss rate of almost 50% in untreated 
homozygous women for classic homocystinuna Recently, the embryotoxicity of a 
high dose of L-homocysteine has been demonstrated to lead to a disturbance in the 
embryologie development in rats (Aerts et al , 1993) In vitro studies in the rat have 
also shown that a shortage of methionine in the culture medium could be related to a 
disturbance in the morphogenesis of the embryo, and the development of NTDs in 
particular (Coelho et al , 1987, Coelho and Klein, 1990) 
Accumulation of homocysteine is known to have a toxic influence on endothelial 
cells (Groot de et al , 1983, Starkebaum and Harlan, 1986) Elevated blood levels of 
homocysteine have been shown to be a risk factor for premature vascular disease 
(Boers et al , 1985a, Clarke et al , 1991 ) Thus, these findings lead to the hypothesis 
that hyperhomocysteinaemia, apart from being a risk factor in the development of 
NTDs, might also be involved in abnormal placental vascularization leading to 
recurrent spontaneous abortion or abruptio placentae 
The objectives of this thesis can be summarized as follows 
1 to study the impact of hormones on folate kinetics and homocysteine metabol-
ism, 
2 to study homocysteine metabolism in cases with abnormal pregnancy outcome, 
in particular with NTDs 
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Chapter 2 
REVIEW OF THE LITERATURE* 
2.1 NEURAL-TUBE DEFECTS 
Definition of neural-tube defects 
In man, NTDs account for the majority of congenital malformations of the central 
nervous system. The neural-tube is formed after a process of primary neurulation 
when invagination of the ectodermal neural-plate along its central axis and fusion of 
the neural-folds takes place, followed by a secondary neurulation process: forma-
tion of the most caudal part of the spinal cord (Schoenwolf and Smith, 1990). The 
development of the neural-tube is schematically shown in figure 2.1. 
The neural-tube development in the human takes place between the 15th and 28th 
postconceptional day, i.e., between the 29th and 42nd day of gestational age 
(Cockcroft 1991). A disturbance in the primary or secondary neurulation process 
results in the so called NTDs. Recently, post-closure rupture of the neural-tube has 
been postulated as a mechanism of NTD formation and may well account for some 
cases of NTDs in man (Hook 1992). 
Although there is no universally accepted classification of NTDs, they can be 
subdivided in complete and partial rachischisis (Sadler et al., 1988). Complete 
rachischisis (craniorachischisis) is defined as a birth defect in which anencephaly is 
complicated by a continuous closure defect of the neural-tube. Partial rachischisis 
involves malformations of the brain or spinal cord, and is subdivided in open and 
closed defects of the neural-tube. Exencephaly and anencephaly are considered 
open NTDs involving the brain, and meningocele and meningo(hydro)encephalo-
cele are classified as closed brain defects. Meningomyeloschisis (spina bifida 
aperta) is considered an open defect involving the spinal cord, whereas spina bifida 
occulta and meningo(myelo)cele are closed spinal cord defects. 
Although NTDs may be a feature of purely genetic disorders (chromosomal or 
single gene defects), the majority results from an interaction between environmental 
factors in a genetically susceptible embryo (Carter 1969). Recognized causes of 
NTDs are given in table 2.1. 
Paris of this review are published: 
* Steegers-Theunissen RPM, Smithells RW, Eske.s TKAB. Update of new risk factors and prevention 
of neural-tube defects Obstet Gynecol Surv 1993:48.287-293. 
* Steegers-Theunissen RPM, Boers GHJ. Eskes TKAB Preventie van afwijkingen van de neurale-
buis door middel van foliumzuur. Ned Tijdschr Geneeskd 1993; 26' 1294-1298. 
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Figure 2.1 The development of the neural-tube (modified from Hamilton et al., 1959); A,B,C and D 
transverse sections through the embryonic disc, and two dorsal views of the embryo 
The clinical consequences of NTDs are severe. Anencephaly is incompatible 
with life. Meningomyelocele usually causes extensive paralysis and anaesthesia 
below the level of the lesion, often with associated hydrocephaly, orthopaedic pro-
blems, and later on impairment of renal and pulmonary function. Nowadays, the 
most common intervention following prenatal diagnosis of NTDs is termination of 
pregnancy. 
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Table 2 1 Recogni/ed causes ol NTDs (modified from Holmesel al 1976) 
MULTIFACTORIAI INHERITANCE 
anencephaly menmgo(mvelo)cclc' and encephalocele 
SINGLE MUTANT GENES 
Meckel s\ndiome autosomal recessive occipital cnccphalocele and rarely anencephaly 
Median tieft ¡ace wndi ome possible autosomal dominant anterior cnccphalocele 
Robeil Twi</u>we-aulosomal recessive anteriorenccphalocclc 
S\ndi ome of anieiior social meniiigoimeloi ele and anal wewnn-dominant either autosomal οι 
X-linked 
Jaico Le\m wndiome autosomal recessive including meningomyelocele 
HARDL SMidiome autosomal recessive encephalocele 
CHROMOSOMAL ABNORMALIT1FS 
13/IXmsnim 
Triploul 
Ollici г such as unbalanced translocation and ring chromosome 
PROBABLY HERFDITARY (unknown mode of transmission) 
5\ ndrome of ос с ipilal ciicephaloc ele iiwopui and retinal d\ splasia 
Anteitoi encephalocele 
TERATOGENS 
Vcilpmic acid spina bifida 
Caibainazepme spina bihda 
Anunoptenn anencephaly and encephalocele 
MATERNAL PREDISPOSING FACTORS 
Diabetes Melimi·, caudal regression with spina bifida 
Folic acid shortage anencephaly and spina bihda 
Epidemiology of neural-tube defects 
The total birth prevalence of NTDs is designated as the proportion oí live births, 
stillbirths and induced abortions with a NTD compared to the total live and still-
births in the population (Cornel et al , 1993, EUROCAT Working Group 1991) This 
figure is influenced by the definition and the ascertainment of registration ot these 
birth delects which is based on birth and death certificates, maternity and hospital 
records and reports of cytogenetic, pathological and neurological examination ll is 
of importance to note that the frequency of NTDs in spontaneous abortion is ten-
fold increased as compared with the NTD figure in term births (Creasy and 
Alberman, 1976, Byrne and Warburton, 1986) Unfortunately, abortion products are 
often not pathologically examined, and are only included in the EUROCAT-registry 
if pathological examination is carried out (EUROCAT Working Group 1991) The 
International Clearinghouse registry provides the NTD prevalence frequencies per 
10,000 infants, which are the proportions ot live- and stillborn infants affected with 
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a NTD per 10.000 live- and stillborn infants in the populations covered, in several 
countries with the exception of The Netherlands, in which such a registry is not pre­
sent. The EUROCAT-registry counts birth prevalence frequencies in 20 regions of 
Europe, including the Northern and South-Western part of The Netherlands 
(EUROCAT Working Group 1991). The recurrence prevalence for NTDs tends to 
reflect the population prevalence, the risk after one NTD being about 10 limes the 
population risk (Elwood and Elwood, 1980). 
The prevalence of NTDs vanes between different countries and between diffe­
rent socioeconomic and ethnic groups. In The Netherlands the total birth prevalence 
of NTDs is low, i.e., 1 in 700. which means that each year around 250 infants with a 
NTD are born. A total of 4 to 6 of' these occurs after a previous pregnancy affected 
with a NTD (EUROCAT Working Group 1991 ). 
anencephaly -
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Hgure 2 2 The diagiam summaiizes the average prevalence frequencies of spina bifida and of anen-
cephaly lortheyeais 1974-1988 (modilied from International Clearinghouse 1991) 
In the Northern part of The Netherlands the total birth prevalence of NTDs ap­
peared to be relatively high ( 1.43 per 1.000) as compared with low prevalence areas 
in Europe (1.1 per 1.000). In low risk areas such as France and Denmark the preva­
lence frequency of NTDs is between 1.1 and 1.3 per 1.000 infants. It is about 7 per 
1,000 births among Sikhs, and even higher rates have been reported in the past, i.e., 
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up to 12 per 1.000 in the coal-mining \alleys ot South Wales (Elwood and Elwood, 
1980: Laurence el al.. 1967) 
As tai as subgroups of NTDs are concerned, the prevalence frequency ol in parti-
cular spina bifida vanes between 3 and 6 per 10.000 ïnlants. but highei figures aie 
seen in Hungary, Australia, New Zealand. Canada. South America, and especially in 
Northern Ireland and Mexico (International Clearinghouse 1991 ). The frequencies 
are declining in England-Wales, Northern Ireland. Hungary and New Zealand, 
while an increasing trend is shown in Mexico and possibly Israel A remarkably 
high prevalence Irequency of anencephaly is counted in Mexico (18 pei 10.000 
infants) and England-Wales ( 11 per 10,000 mlants). In figure 2.2 the avei age pieva-
lence frequencies of spina bifida and anencephaly are shown in various countries 
and renions. 
2 2 VITAMIN DEFICIENCY AND NEURAL-TUBE DEFECTS IN MAN 
Observational studies 
Smilhells et al. (1976) first determined the levels ot serum and red cell folate, 
white cell vitamin C, and vitamin B2 as the nbollavin saturation index in a group of 
over 900 mothers during the first tnmestei of piegnancy. which is after the period of 
neural- tube closure. All mothers participated on a voluntary basis. Six of them gave 
birth to an infant with a NTD. and they showed significantly lower concentrations of 
first trimester red cell folate and vitamin C, and sei um folate and vitamin B2 levels 
tended to be lowei than in controls The determined vitamin levels in the total study 
group showed social class differences This has been confirmed by a subsequent 
dietary study of the same investigators, in which the seven-day food intake records 
ot 195 motheis were studied in the first tnmesler of pregnancy in Leeds (U.K.) 
(Smithells et al., 1977). They demonstrated a significantly higher mean daily intake 
of total and free folate, vitamin A. B2. С and D. iron and proteins in motheis belong­
ing to an upper social class. No infants with a NTD were boi η out ol these mothers 
These observations led to an interest in nutritional factors in the aetiology ot 
NTDs. and this has opened the door to biochemical and metabolic discoveries of 
considerable interest. Howevei, before reviewing the results of the dietary surveys. 
it is important to emphasize the difficulties of dietary studies. The establishment ot 
dietary nutrients requires an accurate record of food consumption and knowledge ot 
the nutrient content of foods Dietary intakes may be determined by 24-hour recall 
"Tell me exactly what you have eaten and drunk during the past 24 houis" by use ot 
a food check-list "How frequently, and in what quantities, do you normally eat the 
following foods'?" or by weighing and recording food eaten over a period of 3 to 7 
days. The most accurate methods are the most time-consuming and lequire full 
cooperation from the person surveyed The nutrient content of manufactured foods 
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may bc changed by the manufacturers without announcement, whereas the nutrient 
content of "natural" foods may show seasonal variations (e.g., vitamin D in butter). 
Dietary surveys are therefore approximations, but if two groups are compared by 
the same observers using the same technique over the same period, the comparison 
is likely tobe valid. 
Laurence el al. ( 1983) studied retrospectively the quality of diets of 415 mothers, 
who had a child with a NTD between 1954-1974 in South Wales (U.K.). This was 
called the interpregnancy diet. They were classified according to whether their diets 
were judged to be "good", "fair" or "poor". "Good" diets were those comprising a 
large variety of foods including particularly meats, eggs and milk, green vegetables 
and fruit, and with a relatively low consumption of confectionary and soft drinks. 
Such a diet can be expected to provide generous intakes of all nutrients, including 
folic acid. "Poor" diets were restricted in variety, with low intakes of animal foods, 
including milk, and oí truit and vegetables, and an overdependence on foods high in 
carbohydrate and fat. These diets were often associated with a high consumption of 
confectionary, and would provide marginal intakes of vitamins and minerals. The 
diets judged to be "fair" were intermediate between these extremes, but in addition 
were thought to provide low intakes of one or more nutrients. Blood samples were 
taken after the interview. A correlation was found between the mean serum and red 
cell folate concentration and the quality of the diet. 
Their subsequent prospective study was conducted between 1974-1979 largely in 
West Glamorgan (Laurence et al., 1983). A dietary history was taken of 244 mothers 
who had a NTD infant and they were compared with a control group of 123 of their 
sisters, who had had only normal babies, and a group of 50 mothers belonging to an 
upper social class. The dietary investigation was more detailed in this study than in 
the first prospective one. In a subset of mothers receiving apparently fair diets were 
reclassified as being "fair but unbalanced", they used excessive amounts of refined 
carbohydrates and fats. Therefore, they were subsequently included within the poor 
diet group. They found that 417c of the mothers with a NTD infant, 26c/c of their sis-
ters and 6% of the upper social class mothers were taking a fair but unbalanced or 
poor diet. All 5 NTD recurrences out of 176 pregnancies of mothers with a previous 
NTD infant were from mothers on poor diets. 
Recently, Mills et al. (1992) published the results of their population based case-
control study. In maternal blood drawn early in 89 pregnancies resulting in NTD 
offspring and in 178 control pregnancies taken from the Finnish Registry of 
Congenital Malformations, the concentrations of folate, vitamin B12 and vitamin A 
were measured. NTD-case mothers and controls were interviewed retrospectively 
about the use of vitamin supplements around the period of neural-tube closure, 
medical conditions, medication exposure, the type of NTD, employment status, and 
family history. Only 9% of mothers with a NTD pregnancy and 10.6% of controls 
used vitamins before the period of neural-tube closure (P= 0.62). NTD-case 
Il 
mothers with obvious causes unrelated to vitamin deficiencies were excluded tiom 
analysis as well as subjects whose samples were collected Π weeks allei concep­
tion The results ol this study conducted in a low risk area toi NTDs demolistiated 
no relationship between maternal seium folate, vitamin B) 2 or vitamin A levels in 
early pregnancy and the risk ot NTDs 
In several studies the possible relationship has been investigated between 
maternal vitamin supplementation (prescribed or selt-adminislcred) around the 
time ot conception and the frequency ot NTDs in their offspring In Western 
Australia, Bower and Stanley (1989) conducted a case control study in which 
dietary folate and multivitamin supplementation, including tolic acid duimg the 
period betöre and during pregnancy was assessed post paitum by a checklist ol 
foods and a 24-hour recall on the diet in 1S4 noi mal 77 NTD affected and 77 conti ol 
pregnancies with birth defects other than NTDs (table 2 2) The day after the 24-
hour recall a sample of blood was collected from the molhei for the estimation ol 
serum and red cell folate levels A protective effect was shown tiom an incieasing 
maternal intake ol folate, especially free folate (mono- ohgoglutamates) and pos 
sibly vitamin C, in the first 6 weeks ot pregnancy However, the interpretation of the 
results is difficult because of recall bias and the use ot vitamin preparations by many 
mothers at the time ot blood sampling 
Mulinare et al (1988) used data from the Atlanta Birth Defects case-control 
study from 1968-1980 to investigate penconceptional multivitamin supplementa-
tion and the birth prevalence of anencephaly or spina bifida (table 2 2) Motheis 
who had had a NTD infant (n= 347) were matched to two control groups (n= 2,829) 
by calendar quarter of birth, race and hospital ot biith With the intention to avoid 
recall bias between mothers of a NTD infant and mothers ol a healthy infant, one 
group of controls consisted of mothers ot a healthy infant and the othei control 
group comprised mothers ot infants with birth detects other than NTDs They were 
interviewed by telephone up to 16 years after the relevant pregnancy regarding the 
supplementation of multi vitamins during the 1 months before and the ~Ί months after 
conception The interviewers weie not informed about pregnancy outcome Despite 
possible recall bias and dilterences in a number of demographic, health related and 
life-style characteristics, multivitamin supplementation was significantly less com­
mon among mothers with a NTD infant than among those ol a malformed infant 
other than NTD, and healthy controls 
A well-designed study by Milunsky et al (1989) was conducted between 1984-
1987 in the area around Boston (U S A ) in which the risk of NTD offspring was 
investigated in relation to maternal multivitamin supplementation with special 
reference to folic acid (table 2 2) Their cohort consisted of more than 22,000 
women undergoing maternal serum screening or amniocentesis toi cx-fctoprotein 
determination around 16 weeks of gestation Interviews were conducted by tele­
phone, usually before the women knew the results ol the test They were questioned 
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about multivitamin supplementation, including folic acid, and about their diet in the 
3 months before pregnancy and the hrst 8 weeks of pregnancy Women were classi-
fied as supplemented if they took one multivitamin tablet containing 0 I to 1 0 mg 
folic acid at least once weekly The NTD birth prevalence among women who took 
no multivitamins before oi after conception was 3 5 per 1,000 compared with 1 2 
per 1.000 tor women who took folic acid containing multivitamins during the 6-
month period The NTD birth prevalence was 3 3 per 1,000 for women taking multi-
vitamins without folic acid in the first 6 weeks of pregnancy, and 0 9 per 1 000 for 
women who took folic acid-containing preparations only during the same penod 
There was no protective effect if folic acid preparations were staited after the 6th 
week of pregnancy, noellect from other vitamins, and an independent nsk from low 
dietary folate intake In addition, a protective el feci was shown with daily intakes of 
100 mg dietary folate or more in the nonsupplemented mothers Howevei the study 
population was not representative ol the general population, because a quartei of the 
women had a NTD family history and 967c was white and 7 0 ^ had been college-
educated 
In contrast to these studies are the negative results of a large, carefully designed 
and analyzed case-control study conducted by Mills et al ( 1989) in California and 
Illinois (U S A »between 1985 and 1987 (table 2 2) Mothers who had had an infant 
with a NTD (n= 571). another birth defect oi stillbirth (n= 546). oi a noi mal înlant 
(n= 573) were intet viewed within 5 months after the diagnosis of the malformation 
or the birth of the infant The first interviewer ascertained the nature of the detect 
and the critical period for multivitamin exposure The second interviewer, who was 
unaware of the pregnancy outcome, obtained information about penconceplional 
multivitamin supplementation, diet, exposures, demographic charactenstics and 
medical, obstetric and social history Multivitamin supplementation was noli tied 
from 44 days before conception until the 31 st postconceptional day In addition the 
maternal intake of lolic acid and other vitamins was studied from the reported intake 
of fortified cereals Mothers were classified as "fully" supplemented it they look 
supplements containing the Recommended Dietary Allowance (RDA) or a higher 
dose at least six days pei week 'Partially" supplemented mothers were considered 
those who consumed less than the RDA, and "nonsupplemented" il no vitamins 
were consumed No significant ditterences were found in the ι ate ol penconcep-
tional multivitamin supplementation between mothers with a NTD ìnlant and both 
control groups This might have been due to misclassification of the group mothers 
starting multivitamin supplementation after conception who were classified as non-
supplemented even it they took vitamins before the time of neural-tube closure 
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Intervention studies 
Non-randomized multivitamin supplementation studies 
In the early 1980s the first non-randomized study conducted at six regional cen­
tres in the U.K. on the prevention of NTDs by dietary measures or multivitamin sup­
plementation was published by Smithells et al. ( 1980). Because two ethical commit­
tees refused to give permission for a randomized clinical trial, no randomization 
took place in this study. The participating mothers, who had had one or more pre­
vious infants with a NTD were given a multivitamin preparation Pregnavite Forte F 
(Bencard), one tablet three times a day, each containing folic acid (0.12 mg), vita­
min С, В,, B2, B6, A/D, and nicotinamide for at least 28 days prior to conception 
until the date of the second missed menstrual period. "Partially" supplemented 
women were those who were either pregnant less than 28 days after starting tablets, 
or who missed taking the tablets on more than one day (see Sheppard et al. (1989)). 
The "nonsupplemented" group consisted of women who were already pregnant 
when referred to the participating centre. The NTD recurrence frequency in the 
informative pregnancies of "fully" supplemented women was 1/178 (0.6%) com­
pared with 13/260 (5.0%) in those of "nonsupplemented" women. This significant 
protective effect of multivitamin supplementation has been confirmed in an exten­
sion of the same study (table 2.3) (Smithells el al., 1983). This study was continued 
in some parts of the U.K. and Northern Ireland. The final results have been pub­
lished recently (table 2.4). 
In addition, Nevin and Seller (1990) compared the effectiveness of periconcep-
tional vitamin supplementation in Northern Ireland with a high NTD prevalence and 
South-East England with a low NTD prevalence and observed a reduction in the 
NTD recurrence frequency, most marked in the high prevalence area of Northern 
Ireland (table 2.4). 
So, although a protective effect of multivitamin supplementation was suggested 
by the studies of Smithells et al. (1989) the most serious criticisms were that sup-
Table 2 4 Final results U К multicentre trial (Smithells et al, 1989. Nevin and Seller, 1990) 
Regions NTD per women with previous NTD Effect 
alfectcd pregnancy 
Fully supplemented' Nonsupplemented 
Yorkshire 1/150(0 7%) 18/320(5 69!) 88% risk reduction 
Northern Ireland 4/511(0.8%) 17/353(4.8%) 83% risk reduction 
South-East England 8/457(18%) "* (4 09!) 55% risk reduction 
" Pregnavite Forte F. 360 pg folic acid per day 
** No comparable figures tor "nonsupplemented" at risk women, but they are at a 4% recurrence fre­
quency. 
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plemented mothers may have been a selfselected group more frequently belonging 
to a higher social class and living in an area with a lower NTD risk than late-entry 
nonsupplemented women who showed an increased prevalence of preceding spon­
taneous abortions and lived in high risk areas This was the reason to reanalyse the 
data and to take into account the above mentioned risk factors (Wild et al, 1986) 
Fortunately, none of these factors was found to have a significant impact on the con­
clusions of the study 
Sheppard el al (1989) studied the NTD recurrence frequency in 2 И mothers who 
were partially supplemented with a multivitamin preparation The recurrence fre­
quency was similar to the rate in the fully supplemented group, ι e , 2 out of 213 
(0 9%) 
In a non randomized study in Cuba, mothers (n= 81) with previously a NTD 
infant received one tablet ot 5 0 mg folic acid per day from at least one menstrual 
period before conception until the 10th postconceptional week (Vergei et al 1990) 
Nonsupplemented women (n= 114) were already pregnant when referred The NTD 
recurrence rates in the groups are given in table 2 3 Their results suggest that folic 
acid supplementation might be an effective method in the primary prevention ot 
NTDs 
Randomized xitamin supplementation studies 
In accordance with the lindings ol the non randomized studies were the conclu­
sions from several randomized trials (table 2 3) A small, randomized, double-blind 
trial was conducted in which women with a previous history of NTD received either 
folic acid 4 0 mg daily or placebo (Laurence et al , 1981) The NTD recurrence fre­
quency in the supplemented mothers (n=60) was not significantly different from the 
placebo group (n= 51 ) However, on the basis of serum folate measurements it was 
concluded that almost one-third ot women (n= 16) in the folate supplemented group 
had not taken their tablets When these noncompliers were added to the placebo 
group all NTD recurrences were to women in this group (6/67) Although, the 
results are very suggestive of a protective effect ot penconceptional folic acid sup­
plementation, the study population was very small Moreover, to consider women as 
noncompher solely on the basis ot a serum folate level of < 10 μg/mL takes no 
account of a possible disordei in folate absorption or metabolism Such a disordei 
has been suggested by Hibbard and Smithells (1965) who demonstrated a disturbed 
tormiminoglutamic acid-excretion test (FiGlu) in a subset ot women with a fetus 
showing a malformation of the central nervous system This was in line with data 
comparing the dietary folate intake with actual folate levels in blood (Yates et al, 
1987) 
Ot great importance are the results of the U К MRC Vitamin Study Research 
Group (1991) and the very recently published results of the randomized study of 
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Czei7el and Dudas (1992) The first investigation was a double-blind, randomized 
multivitamin study conducted at 11 centres in 7 countries (table 2 3) Women with a 
previous NTD infant were randomly divided in tour supplementation groups before 
anextpiegnancy A, folic acid only, B, folic acid and other vitamins, C, neither folic 
acid nor other vitamins, D. other vitamins A total of 1195 completed informative 
pregnancies appeared to be sufficient to point out a 72c/c protective effect for 4 0 mg 
folic acid supplementation per day The NTD recuirence Irequency was 1 0% in 
women supplemented with folic acid (group A and B) and 1 5% in those not recei­
ving folic acid (group С and D) (relative risk 0 28, 95% confidence interval 0 12-
0 71) Other vitamins showed no significant protective effect 
The double blind, randomized trial of Czeizel and Dudas ( 1992) was performed in 
Hungary and is unique because it is the only study that explores the preventive effect 
of penconceptional folate supplementation on the first occurrence of infants with a 
NTD (table 2 1) The women studied received either a multivitamin preparation 
including folic acid 0 8 mg daily, 11 other vitamins, the minerals calcium, phospho­
rus, magnesium and iron, and the trace-elements copper manganese and zinc (n= 
2104), or a placebo containing the same trace elements and a lower concentration of 
vitamin С (n= 2052) In the vitamin supplemented group none of the infants had a 
NTD, however, 6 NTD pregnancies occurred in the placebo treated group This data 
demonstiates complete reduction of the first occurrence of infants with a NTD by 
penconceptional vitamin use of the mother However, there may be some concern 
whether this effect is due to folate solely, because of the differences in the composi­
tion of the multivitamin preparation and placebo 
Summary 
The reviewed observational investigations studied the NTD-vitamin hypothesis 
retrospectively by measurement of folate and other vitamin levels, dietary analysis 
or the ascertainment of prescribed or self-administered vitamins, focusing on the 
first trimester of pregnancy Problems encountered consisted of recall bias, metho­
dological differences in blood folate measurement and dietary analysis, inaccuracy 
of gestational age and thereby misclassification of maternal multivitamin use in the 
very early stage of pregnancy Notwithstanding that, it is remarkable that so many of 
these observational studies suggest a beneficial effect of penconceptional folic acid 
consumption until the ciitical lrd-4th week ol pregnancy in which neural-tube 
closure takes place 
The conducted intervention studies differed in characteristics of the study popu­
lations, criteria of vitamin supplementation, and the prescriptions used However, 
the results of the U К MRC Vitamin Study Research Group ( 1991 ) and possibly the 
most recent study ol Czeizel and Dudas ( 1992) strongly suggest the beneficial effect 
of penconceptional folic acid treatment to reduce the NTD recurrence and first 
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occurrence frequency. The possible protective effect of other vitamins and trace-
elements in combination with folic acid on the development of NTDs needs further 
investigation. 
2.3 FOLIC ACID 
Introduction 
In 1930 folic acid, vitamin Вц, was first recognized as a factor present in the 
yeast preparation marmite, which was able to cure a megaloblastic anaemia occur­
ring among Hindu women in India, particularly during pregnancy (Wills and Mehta, 
1930). The term "folic acid" (Latin folium, "leaf") for pteroylglutamic acid was 
introduced by Mitchell et al. ( 1941 ), and the substance was successfully synthesized 
in the form of pteroylmonoglutamate by Angier et al. ( 1946). Folic acid and folate 
are the preferred synonyms for pteroylglutamic acid (figure 2.3). 
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Figure 2.3 The structure of folic acid and its derivatives (modified from Rosenblatt 1989) 
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Folic acid comprises a ptendine, p-aminobenzoic acid and glutamic acid The 
natural occurring folates consist ot a large group of derivatives derived from the 
reduction and addition to the basic structure Folates are available in part as small 
molecules with one to three sidechains, ι e , mono- and oligoglutamates, and in part 
as larger molecules, ι e , polyglutamates Folates are present in all body tissues 
Folate is stored to the greatest extent in the polyglutamate form in liver, pancreas, 
kidneys and brain Mono- and oligoglutamates (free folate) and polyglutamates 
together represent "total folate" 
Biochemistry 
Transport mechanism 
The absorption process ot dietary folate (mainly as 5-methylpteroylpolyglutama-
tes) is divided in two steps (figure 2 4) In the first step polyglutamates are con­
verted to monoglutamates by a conjugase present in the jejunum Only monoglu-
tamates or, at most oligoglutamate derivatives are taken up by the intestinal cell 
The second step includes absorption by active as well as passive transport of 
monoglutamates into the intestinal cell In the intestinal cell the absorbed monoglu-
tamates are fully reduced to tetrahydrofolate (THF) by dihydrofolate reductase 
Depending upon folate supply they are 
a) transported directly into the portal circulation, 
b) converted to 5-methyltetrahydrofolate (5-methyl THF) and transported to the 
portal circulation, oi 
c) converted directly into THF-polyglutamate stores 
The stored THF-polyglutamates can be degraded to THF-monoglutamates by 
intracellular conjugase and released into the circulation 5-Methyl-THF-monoglu-
tamate is the predominant form of folate in serum and in many tissues In the liver, 
polyglutamate derivatives of 5-methyl-THF are the major stored folates 
About two-thirds of 5 methyl-THF in serum is loosely bound to a non-specific 
low-affinity folate binder such as albumin A second folate binder has been descri­
bed Although this binder has a high affinity for folate, its capacity is low This pro­
tein may represent a storage form (Waxman and Schreiber, 1973) Blood of the 
umbilical cord contains both low and high affinity folate binders (Kamen and 
Caston, 1975) Folate binding proteins are involved in the transfer of folate against a 
concentration gradient from the mother to the fetus, which suggests active placental 
transport by which the fetus is able to accumulate folate Strelhng (1976) de­
termined higher folate levels in fetal blood as compared with maternal blood The 
placenta seems able to supply the fetus with adequate folate However, little is 
known about folate provision for the growth of the conceptus before the placenta 
has developed 
20 
Food folate 
polyglutamates 
(largely reduced) 
Conjugase 
Mono or Oligoglutamates 
derivatives 
Folic acid (therapeutic) 
( Monoglutamates) 
Intestinal lumen 
5-methyl-THF 
Oligoglutamates 
Conjugase 
Polyglutamates 
? 
5-methyl-THF 
Reduced 
derivatives 
Dihydrofolate 
reductase 
-¿L 
Intestinal cell Portal blood 
Figure 2 4 Summar> ol digestion and absorption of folic acid and dietary folate deinatives by the 
intestinal cell (modified from Rowc 1986) 
Metabolism 
The prime function of folate is to provide one-carbon moieties for the synthesis 
of three of the four bases of DNA, ι e , guanine, adenine, and thymine, as well as for 
synthesis of other compounds These one-carbon moieties are formate required tor 
the synthesis of the purines 5-tormamidoimidazole-4-carboxamide ribonucleotide 
(FA1CAR) and tormylglycinamide ribonucleotide (FGAR), methylene for deoxy-
thymidine synthesis (dTMP). and the methyl group for methionine synthesis 
(Rosenblatt l989;Chanannetal, 1992). The one-carbon moiety is derived from the 
conversion of serine into glycine, formiminoglutamic acid (FiGlu) into glutamic 
acid (Glu) or the cleavage of glycine The folate metabolism in man is depicted in 
figure 2 5 
The vitamin B^-dependent enzyme 5-methyl-THF-homocystcine methyl-trans-
ferase or methionine synthase (EC 2 1 1 Π) catalyses the conversion of 5-methyl-
THF and homocysteine into THF and methionine Methionine reacts with adeno-
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sine to form S-adenosylmethionine S-Adenosylmethionine is the most important 
methyl donor and regulates its own synthesis by inhibition of 5,10-methylene-THF 
reductase (EC 1 1.1 68) and stimulation ot cystathionine synthase (EC 4 2 1 22) 
(see paragraph 2 5 Homocysteine) (Finkelstein 1990) 
Methionine synthase requires reduced vitamin B ) 2 , i.e , methylcobalamin, as co-
factor Cobalamin accepts its methyl group from 5-methyl-THF (Taylor and 
Weissbach, 1969) Both folate and vitamin В12 deficiency will decrease methionine 
formation which may result in decreased levels of S-adenosylmethiomne In 
methylcobalamin deficiency folate is trapped as 5-methyl-THF because methionine 
synthase is the only reaction able to convert 5-methyl-THF into THF (methyl-folate 
trap) (Scott and Weir, 1981). In such cases a functional folate deficiency exists 
although normal to increased folate levels will be present in blood 
Requirement 
Humans are totally dependent on dietary sources of folate, and major contribu­
tors are green leafy vegetables, liver and kidney (table 2 5) Requirements of folate 
can be met by a variety of folate derivatives as long as the essential structure of pte-
roylglutamic acid remains intact (Davis 1986) The inactivation of folate occurs 
after oxidation and exposure to ultraviolet light and heat. Thus, naturally occurring 
folates are lost in storage and cooking Most naturally occurring folates are present 
as polyglutamates This is in contrast to pharmaceutically available folate which 
contains only monoglutamates In the gut monoglutamates are absorbed much faster 
than polyglutamates (see paragraph 2 3 Folic Acid, "Biochemistiy"). 
The demand of folate is increased in infancy, adolescence and pregnancy The 
recommended dietary intake for folate is given in table 2 6 
Table 2 5 Folate conlenl ot selected foods (modified from Expert Adv isory Group 1992) 
Foods 
Liver tried 
Spinach 
Wholemeal bread 
Bananas 
Cabbage 
Brussels sprouts 
Potatoes 
Total lolate 
Ug/100g 
240 
90 
40 
15 
10 
110 
25 
Foods 
Broccoli 
Oranges 
Orangejuice 
Grapetruitjuice 
Tomatoes raw 
Lettuce raw 
Total folate 
μg/100g 
65 
30 
20 
25 
15 
55 
23 
Table 2 6 Recommended dietay intake of folic acid (RDI) (modilied trom Food and Nutrition Council. 
1993) 
male, age > 19 years 
female, age > 19 years 
pregnancy 
lactation 
U S A (RDA) 
1990 
μg/day 
200 
180 
400 
280 
U.K. 
1991 
Ug/day 
200 
200 
300 
260 
FAO*/ 
W H O 
μg/day 
200 
170 
>350 
270 
Nethei lands 
1992 
μg/day 
200-300 
200-300 
400-600 
400-600 
*FAO Food and Agriculture Organization 
*WHO World Health Organization 
Diagnosis of folate deficiency 
Folate deficiency leads to clinical symptoms such as diarrhoea, cheilosis and 
glossitis (Babior and Bunn, 1980). The haematological manifestations of folate 
deficiency are macrocytosis, low reticulocyte, leucocyte and platelet count, aniso-
cytosis, poikilocytosis, macroovalocytes and hypersegmentation of the nucleus of 
the neutrophils. Pathological circumstances resulting in an increased folate require­
ment are: malabsorption due to sprue, restoration of blood cells after loss or haemo­
lysis, alcohol abuse, treatment with folate antagonists (methotrexate) and anti-
epileptic drugs (phenytoin, phénobarbital, primidone) (see paragraph 2.3 Folic 
Acid, "Neural-tube defects"). 
Different methods are available for the measurement of folates. However, they 
are difficult to compare. Serum folate concentrations vary rather widely with 
respect to nutrition, sex and the use of drugs. Folate is incorporated into red cells 
during erythropoiesis. Therefore, red cell polyglutamates reflect a more accurate 
and less variable index of folate status than serum folate levels (Brody et al., 1984). 
Morphologic blood examination showing hypersegmentation of the polymorpho-
nuclear leucocyte nucleus, used to be the best way to diagnose a folate deficiency 
(Davis 1986). Function tests to determine folate status include the deoxyundine 
suppression test and the FiGlu function test. Both methods are used to study folate 
levels indirectly. The deoxyuridine suppression test is based on the observation that 
in case of folate deficiency the uptake of tritiated thymidine by bone marrow cells is 
suppressed, because of decreased folate dependent conversion of dUMP into dTMP. 
The FiGlu function test is based on the increased urinary excretion of FiGlu after 
histidine loading, because folate deficiency leads to a decreased conversion of 
FiGlu into glutamic acid (Glu) (figure 2.5) (Hibbard 1964). In addition, folate defi-
ciency will result in a mild to moderate hyperhomocysteinaemia. Therefore, the 
determination of the concentration of total homocysteine in blood seems to be a 
valid indirect method as well to diagnose a metabolic folate deficiency (Stabler et 
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al . 1988 Hall and Chu 1990) Microbiologic assays ot folate depend upon the 
metabolic requnemenls ot folate in ceitain microoiganisms Lactobacillus casei is 
generally accepted as the standard assay oiganism, because it responds to the 
gieatest vanety of different folate derivatives (Cossins 1984) A more sophisticated 
technique is the ladioassay based on competitive binding ot labelled and unlabelled 
folates to a limited number of binding sites on a folale-binding protein The results 
ate comparable to microbiologic assays High performance liquid chromatography 
(HPLC) sepaiation ot lolates is favourable when specific lolate derivatives need to 
be measuied (Cossins 1984) 
Genetic disorders of folate metabolism 
Up to now five inherited disoideis of folate metabolism have been described 
These are a) 5 10-methylene-THF leductase deficiency, b) functional 5 methyl-
THF- homocysteine methyltiansteiase (methionine synthase) deficiency, c) glu­
tamate foimiminotransferase deficiency d) hereditaiy folate malabsorption and e) 
dihydiofolate reductase deficiency Their clinical and biochemical characteristics 
aie summaiized in table 2 7 
5 10-mctlnlcne THF leduclase defiuenc\ Mudd et al (1972) hist described 
5 ΙΟ-methylene THF leductase deficiency About thirty patients have been de-
scubed (figure 2 5 conveision 4 and table 2 7) The seventy of the enzyme defi­
ciency and the conesponding level ot S methyl-THF parallels the clinical and bio­
chemical symptoms Clinical symptoms are generalized sei/ures delayed 
psychomotor development, and peripheral neuropathy Seveiely allected patients 
ollen die at infancy oi early childhood (Wong et al , 1977) Patients with mildei 
symptoms tend to survive into adult hie (Mudd et al 1972) Their typical biochemi­
cal chaiactenstics include incieased blood and unnc levels of homocysteine and 
noi mal οι subnoimal blood methionine levels In general, homocystinuna is less 
severe than obseived in patients with a cystathionine synthase deficiency In addi­
tion low folate levels in serum, led cells and ceiebrospinal fluid have been reported 
(Cibe 1975) Notably theie is an absence of megaloblastic anaemia in 5,10 methy-
lenc-THF reductase delicient patients The enzyme delect is inherited in an autoso­
mal recessive ti ait and can be assessed in livei. fibroblasts, lymphocytes and leuco­
cytes Kang el al (1991) recently discovered a 'new variant' of 
5 10-methylene-THF reductase deficiency, which is characterized by the absence of 
neuiological abnormalities, an enzyme activity of about 507c of the normal value, 
and distinctive thermolabihty of the enzyme in lymphocytes Reportedly the inci­
dence ot thermolabile 5 10-methylene THF leductase was У/с in contiols and 17% 
in patients with coronary artery disease This suggests a high mutated gene fre­
quency among the geneial population The mild hypcrhomocysteinaemia assessed 
m some subjects with theimolabile 5 10 methylene-THF reductase was effectively 
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Tabic 2 7 Inheiilcd delects in the metabolism ol lolatc (modilied hom Rosenblatt 1489 Sui lees and 
Leonard 1990) 
Chai attiri si it s MTIIhR 
Cliimal 
Megaloblastic anaimia 
Developmental delay 
Sei/ures 
Penphcial neuiopathy 
Speech abnoimalm 
Apnoe j 
Gail ahnoiinahty 
-
+ 
+ 
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
-
+ 
Methionine synthase Glutamic Heicditaiy 
dehuenc\ loi mimino lolatc 
Chi Chi Chi tiaiislerasc mal 
CG AB C D F deliiiency abruption 
Βίοι humt ui data 
HumocWinuiia 
Homocysleinaemia 
H\ pomethioninaemia 
Low scrum lolatc 
Low led cell folate 
Low scrum B
r 
Increased MMA in mine 
Incicascd FIGLU in urine 
En/уте deticicncv 
detectable in 
Ti calment 
+/-
СЫ 
FiGlu 
M M A 
clinical symptom 
exceptions 
cobalanim 
lormimino] 
mclhylmali 
de sc и 
F Le Li L\ 
belarne 
lolic acid 
methionine 
οι biochemical 
F 
hydioxocobalamin 
lohniL acid 
belarne 
abnormality piescnl/.ibsenl 
bed in some cases 
glutamic acid 
une acid 
Κ 1 ι 
lohe 
-
acid 
h 
К 
1 с 
Li 
ί > 
l i 
lohe acid 
tohnic acid 
Fibroblasts 
Kidncv 
1 eucoc)tcs 
Li\ei 
1 ymphocytcs 
MIHFR S IO mcthylene-THF icductasedclicieiiLN 
tieated by oial folic acid theiapy Because seveie 5.10-methylene-THF ìeduclase 
deficiency is lesistant to folate trealment, betaine is often piesciibed 
Functional methionine wnthase defletette^ (see furthei paiagraph 2 4 Vitamin 
B|2, "Genetic disorders of vitamin Bl2 metabolism") Vitamin B ! 2 as methylcoba-
lamm is an essential colactoi tor methionine synthase, and as adenosylcobalamin 
toi the enzyme melhylmalonyl-CoA mutase (EC 5 4 99 2) Therefore, an enzymatic 
disorder in the synthesis of these cobalamins will lead to a lunctional defect in 
methionine synthase or methylmalonyl CoA mutase activity (ligure 2 5, convei sion 
5. figure 2 7, and table 2 7) The repotted enzymatic detects may affect eithei 
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melhjlcobalamin synthesis (cobalamin E and G mutation), the synthesis of adeno-
sylcobalamm (cobalamin A and В mutation) or both (cobalamin C, D and F muta­
tion) The patients with cobalamin A and В mutations show methylmalonic acidu-
na but no megaloblastosis or homocystinuria (table 2 7) The cobalamin E and G 
mutation lead to homocystinui ia in the absence of methylmalonic aciduria (Schuh et 
al 1984) Cobalamin С D and F mutation show both homocystinuria and methyl­
malonic aciduria (Surlees and Leonard 1990) 
Glutamate foi miminoti ansferase defic іепсл The enzyme glutamate formimino 
transferase (EC 2 1 2 5) is involved in the catabolism of histidine (figure 2 5, con 
version 9 and table 2 7) This pathway may be present only in liver and kidneys and 
îepresents quantitatively a minor single carbon pool Glutamate formiminotrans-
ferase deficiency syndiome an autosomal recessively inherited disease, can be divi-
ded in two ditteient phenotypes The severe type is probably caused by a primary 
block in the cyclodeaminase enzyme (figure 2 5 conversion 10) These patients 
suffei from mental and physical retardation and cortical atrophy Biochemical char-
acteristics are increased FiGlu excretion after histidine loading in spite of abnor 
mally high serum folate and normal vitamin B ) 2 levels (Rosenblatt 1989) The mil 
dei type of the disease may be due to a defect in the glutamate formiminotransferase 
enzyme (table 2 5, conversion 9) and shows excessive excretion of FiGlu, and no 
symptoms of mental retardation (Rosenblatt 1989) The FiGlu excretion and formi 
minoglutamic acidemia, especially aftei histidine loading is hardly influenced by 
treatment with large doses of folate vitamin В ¡2 or serine The effect ot treatment in 
these patients has been judged on the decrease of urinary excretion of FiGlu At pre-
sent the determination of enzyme activity is only possible in hepatocytes 
Defectnt folate absorption An autosomal recessive inherited disorder in the 
absorption of folate was first described by Luhby et al (1961) (figure 2 5, conver 
sion 1 and figure 2 4 and table 2 7) About a dozen patients have been reported who 
fail to absoib oral folic acid monoglutamates or reduced folates (food) (Davis 1986 
Rosenblatt 1989) These folate malabsoiption disorders support the existence of a 
specilic earner mechanism in the transport of folate across the intestinal wall, and 
into the ceiebrospinal fluid The common clinical presentation in hereditary folate 
malabsorption is megaloblastic anaemia, diarrhoea, mouth ulcers, severe physical 
and mental retardation and seizures in the first few months of life Laboratory 
features aie increased FiGlu excretion and low serum folate levels (Corbeel et al , 
1985) Some patients respond to treatment with very large doses of folic acid 
monoglutamatc (up to 40 mg/day) In others the vitamin was successfully given 
intramusculai ly Some showed very low folate levels in the cerebrospinal fluid pos 
sibly due to a transport defect from the serum into the cerebrospinal fluid 
Intramuscular treatment with reduced folates as 5-formyl-THF (folinic acid 
(Leucovorin®)) can pioduce neurologic improvement (Rosenblatt 1989) 
Dilndiofolate leduttase deficiency A rare inherited disorder, dihydrofolate 
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reductase deficiency has been reported in 3 cases (ligure 2 5. conveision 2) 
Depending on the degree of enzyme deficiency this disease piesents in infancy and 
may result in stillbirths and spontaneous abortions during reproductive lite (Tauro et 
al 1976, Walters 1987) Clinical symptoms oí surviving infants are failure to 
thrive severe megaloblastic anaemia glossitis mental retai dation and splenic 
enlargement The diagnosis is based primarily on low hepatic levels of dihydroio 
late reductase activity Treatment with Leucovoi in® bypasses the en/yme block and 
corrects the defect (figure 2 5) 
Neural-tube defects 
Pregnant women are prone to develop a folate deficiency probably due to their 
increased folate demands for the growing fetal and maternal tissues (Chanai in et al 
1968, Hall et al , 1976 Bruinse et al , 1985) Other factors piovoking folate deh 
ciency include poor diet the physiological haemodilution of pregnancy incieased 
plasma clearance and hormonal influences (Shojania 1984) 
In 1952 Thiersch reported an association between NTDs and prenatal exposure lo 
folate antagonists in man such as aminoptenn A higher prevalence of birth detects 
has been reported in the offspring of folate-dehcient mothers (3%), judged by an 
increased urinary excretion of FiGlu after histidine loading than in commis (1 67r ) 
(Hibbard 1964) However, the difference was not statistically significant and the 
malformations did not include NTDs A link between folate deficiency and human 
fetal malformations, in particular central nervous system malformations including 
NTDs, was first reported by Hibbard and Smithells (1965) The piesence of an 
underlying defect of folate metabolism, either preceding or precipitated by the 
increased demands of folate during pregnancy was suggested This was concluded 
from the results of the FiGlu tests which were carried out in late pregnancy or very 
early post partum in mothers of infants with a malformation and in matched controls 
being mothers of healthy offspring The mothers of an infant with a central nervous 
system malformation showed an abnormal FiGlu test in 69% as compared with 17% 
of matched control mothers of normal control infants Yates el al (1987) demonstra-
ted an association between NTD births and low levels of maternal red cell folate 
which could not be entirely attributed to lower dietary intake of folate In this study 
vitamin levels were measured in twenty women who previously had two or more 
NTD pregnancies Each index case was compared with a Iemale control matched 
for age, obstetrical history and social class The mean red cell folate concentration 
was 178 ng/mL in the group of NTD mothers and 268 ng/mL in the control group 
This difference was statistically significant Because the red cell folate levels were 
lowest in mothers who had three or four previous NTD pregnancies, they hypothesi 
zed that a maternal genetic disorder of lolate metabolism was responsible for the 
development of NTDs Other investigations were not able to confirm these findings 
(Hall 1972, Molloy et a l . 1985) 
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The NTD prevalence in the products ot" spontaneous abortion is ten-fold in-
creased as compared to the prevalence at birth (Creasy and Alberman, 1976: Byrne 
and Warburton. 1986). Regarding this, it is of' interest that a possible relationship has 
been demonstrated between increased spontaneous abortion and folate deficiency 
by Hibbard in 1964. He found an increased FiGlu excretion after histidine loading in 
}2'7r of 131 women with isolated unexplained abortion, and in 60.59r of women 
with two or more recurrent spontaneous abortions. 
Women taking antiepileplic drugs for the treatment of epilepsy have an increased 
risk of having an infant with a congenital malformation, particularly congenital 
heart disease, facial cleft, and NTD (Robert and Guibaud. 1981; Kelly 1984). 
Meadow ( 1968) speculated that the teratogenicity of antiepileptic drugs may reside 
in the induction of folate deficiency. This is supported by the relationship between 
the use of antiepileptic drugs, folate levels and adverse pregnancy outcome, inclu-
ding spontaneous abortions and congenital malformations (Dansky et al.. 1987). 
Antiepileptic drugs such as phénobarbital, phenyloin and primidone can reduce 
folate levels by inhibiting intestinal absorption or by increasing folate turn-overdue 
to induction of the cytochrome P45Q glucuronyl transferase enzymes (Kelly et al.. 
1979: Perucca 1987). The maternal use of valproic acid and carbamazepine is consi-
dered to increase the risk of spina bifida in particular (Dalens et al.. 1980: Bjerkedal 
et al., 1982; Robert and Guibaud, 1982; Lindhout and Schmidt. 1986; Rosa 1991). 
For both antiepileplic drugs no strong evidence is available for the presence of 
abnormally low serum folate levels, but several studies report some form of interfe-
rence with folate metabolism (Hendel et al.. 1984; Carl 1986; Carl 1990). Recently, 
in mice it has been demonstrated that valproic acid interferes with the conversion of 
THF into 5-formyl-THF. which is possibly due to inhibition of the enzyme glu-
tamate formyltransferase. through which the teratogenicity of valproic acid may be 
explained by an altered folate metabolism (Wegnerand Nau, 1992). 
In case a lack of maternal folate in early pregnancy predisposes to the develop-
ment of NTDs. these malformations might be prevented by folic acid supplementa-
tion. The effect of vitamins on NTD birth prevalence and recurrence figures are 
described in paragraph 2.2 Vitamin deficiencies and neural-tube defects in man. 
"Intervention studies". Biale and Lewenthal (1984) prescribed folic acid tablets to 
epileptic women using antiepileptic drugs and concluded a reduced risk of congeni-
tal malformations. However, there have been some criticisms on this study, i.e.. his-
torical controls were used; no tests of compliance were incorporated, and several 
women participated more than once. 
Although folate is generally accepted as non-toxic in man. high-dose folic acid 
supplementation may have several disadvantages. A high dose of folic acid (> 1.0 
mg folic acid per day) may mask the haemaiologic effects of vitamin B ]2 deficiency, 
while its neurologic manifestations progress (Herbert 1992). Possible risks of a high 
level of circulating folate are noted by Scott and Weir (1991 ). Folic acid is a neuro-
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toxin and causes convulsions in laboratory animals Although the blood/biain 
barrier normally restricts access of folic acid in such way that very high doses are 
required to produce these effects similar toxicity occuis at much lower doses it the 
blood/biain barrier is damaged In epileptic women, therelore supplementation of 
folic acid with doses similai to that used in the MRC trial will probably result in 
increased seizuie frequency (Strauss 1974) As the developed brain may be pro 
tected from the neurotoxic etleclsot synthetic lolic acid by the blood/biain banier 
it is unknown whether neuial tissue during very early embryonic development is 
protected 
A low dose of folic acid may also be favourable as it is unclear whether a high 
dose folate interferes with the transtei and metabolism of /mc in man, especially in 
cases with a marginal zinc status (Milne el al, 1984) This may be impoitani as diet­
ary 7inc deficiency and a ι elative shoilage of maternal zinc has been associated with 
NTDs in human (Cavdar et al , 1988, Milunsky et al . 1992) Furthermoie the fin­
dings of Quinn et al (1990) suggest that in the presence of a /ine deficiency the 
administration of high-dose lolate increases the teiatogenicity of such a deficiency 
The enzyme γ-glutamyl hydrolase is /inc-dependent and conveils polyglutamates to 
monoglutamates, which is an important step in the absoiption of folate Theretoie, 
the availability of folate is dependent on the activity ol γ-glutamyl hydiolase which 
is regulated by the concentration of zinc (Canton et al 1990) 
2 4 VITAMIN В 1 2 
Introduction 
The complete thiee-dimensional structure of vitamin B| 2 , ie cobalamin, was 
published in 1955 (figure 2 6) (Friedlich 1988) It consists of a porphynn-like 
macro-ring with a cenital coball atom, a nucleotide and a second cobalt-bound 
group (CN H2O, etc), which is situated within a cornn ring Vitamin В ,2 is piesenl 
in man as hydroxocobalamin and the active forms methylcobalamin and adenosyl 
cobalamin Methylcobalamin is the cotactoi for the enzyme methionine synthase 
and adenosylcobalamin for melhylmalon CoA mutase (tiguie 2 7) (F-enton and 
Rosenberg, 1989) The most common commeicial form is cyanocobalamin which 
has to be converted to one of the biologically active forms belore it can be utilized 
(Cooper and Rosenblatt 1987) 
Biochemistry 
Transpoi t and in trac ellular met hanism s 
Cobalamin is released from dietary protein in the stomach and bound to R- pro-
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FigLiie 2 (Ì The stiuclure of vitamin B | : (modified from Feritori and Rosenberg. 1989) 
teins of salivary and gastric origin (figure 2.7). R-proteins are glycoproteins with 
high affinity for cobalamin. Pancreatic proteases digest the R-proteins, thereby re-
leasing cobalamin in the upper small intestine, where it is bound to intrinsic factor, a 
glycoprotein secreted by the parietal cells of the stomach. In the terminal ileum the 
intrinsic factor cobalamin complex (Cbl-IF) binds to specific receptors on the 
mucosal brush border, thereby enabling the vitamin to be absorbed. The active 
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Figure 2 7 Cellular and subcellular activity of cobalamin (modified from Surtees and Leonard 1990) 
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absorption is limited to about 2-3 mg cobalamin from a meal After endocytosis and 
passing across the basement membrane, cobalamins enter the portal circulation and 
bind to transcobalamin-2 This transport IJ-globulin protein facilitates the cellular 
uptake ot vitamin B 1 2 by liver, bone marrow and other cells More than ninety per­
cent of circulating cobalamin is bound to transcobalamin-1, a glycoprotein closely 
related to gastric R-binder and derived in part tiom leucocytes Together with trans 
cobalamin-3 they carry the steady state cobalamin in serum 
Intracellularly. cobalamin is released from the complex and is either converted to 
methylcobalamin or enters the mitochondrion After reduction and adenosylalion 
adenosylcobalaimn is formed and bound to melhylmalonyl-CoA mutase 
Vitamin B p is the only water-soluble vitamin that is stored in considerable 
amounts in the liver, ι e 2 0 mg. with seventy percent present as adenosylcobala­
imn and Ι -3 percent as methylcobalamin A similar disti lbution is seen in red cells, 
kidney and brain However, the majoi circulating cobalamin is methylcobalamin, 
accounting tor sixty to eighty peicent of total plasma vitamin B ] 2 , followed by ade­
nosylcobalaimn (23%), hydroxocobalamin (10%), and cyanocobalamin (2%) 
(Fenton and Rosenberg. 1989. Cooper and Rosenblatt, 1987, Friedrich 1988) 
Metabolism 
Methylcobalamin (MeCbl) is an essential cofactorin theintracellulai conveision 
ol homocysteine to methionine by methionine synthase (figure 2 7, conversion 7) 
Cells which are primarily deficient in vitamin В
 ( 2 could be secondarily deficient in 
folate, because 5-methyl THF cannot be converted by methionine synthase to other 
forms of THF This is the so-called methyl-folate trap hypothesis, see paragraph 2 3 
Folic Acid. "Biochemistry" (Scott and Wen, 1981 Chanann et al . 1992) Since, 5-
methyl-THF is a poor substrate in the formation of 5-methyl-polyglutamate, it 
largely remains in the unconjugated form and leaks from the ceil This causes a 
tissue THF deficiency resulting in megaloblastic anaemia despite high total folate 
blood levels Also the folate stores, in particular THF-polyglutamate lorms, will be 
reduced in vitamin B ! 2 deficiency For this reason large doses ot folate can produce 
a partial haematologic remission in vitamin B ] 2 deficient patients with haematolo-
gic complications However, as a result ot vitamin B ] 2 deficiency also the conver­
sion of homocysteine to methionine is reduced, which may cause the neurological 
complications associated with vitamin Вj2 deficiency Methionine is essential in 
the production of choline, choline-containing phospholipids and myelin basic 
protein 
Requirement 
In man, the supply ot vitamin Β ρ is derived from meat, dairy products and pro-
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auction by microorganism in the gul. Vitamin B 1 2 deficiency caused by malnutri­
tion is rare, and sometimes occurs in strict vegetarians. Because of the effective 
entero-hepatic recycling of vitamin B 1 2 from bile and other intestinal secretions, the 
turnover rate is relatively slow. Although pregnancy is not a predisposing factor for 
the development of vitamin В,
 2 deficiency, it is associated with a steady and physio­
logic fall of serum vitamin B| 2 dueto transfer to the fetus, haemodilution, hormonal 
influences and changes in vitamin B,2 binding (Green et al.. 1975). Vitamin B ] 2 
deficiency during pregnancy is most likely due to an underlying condition such as 
tropical sprue or vegetarianism. The recommended dietary allowance of vitamin 
B | 2 is given in table 2.8. 
Table 2 8 Recommended dietary allowance (KDA)ol vitamin В,
:
 (modified Irom llerbertct al , 1992) 
Category Age Indi\ idu.il RDA μg/day 
Females > 11 year 2 0 
Males > 11 yeai 2 0 
Chilchen Ü I year 0 3-0.5 
I-10 year 0 7-14 
Piegnancy 0-4 months 2 2 
Lactation 0-> fi months 2 6 
Diagnosis of vitamin B ] 2 deficiency 
The most common cause of vitamin B I 2 deficiency is a lack of intrinsic factor 
caused by atrophy of the gastric mucosa. Vitamin B ] 2 deficiency also occurs after 
gastrectomy, ileal abnormalities or colonization of the small intestine by large mas-
ses of bacteria or in extreme vegetarianism (Babiorand Bunn. 1980). 
Major clinical symptoms of vitamin В , 2 deficiency are pernicious anaemia, diar­
rhoea, cheilosis and glossitis which are similar but less severe and widespread than 
in cases of folate deficiency. The neurologic symptoms are alarming, because com­
plete remission after treatment is often not attained. The neurological complications 
involve demyclinization of peripheral nerves, spinal cord, posterior and lateral 
columns and cerebrum tollowed by axonal degeneration and finally neuronal death. 
These neurologic symptoms can even occur with a normal haematocrit and no signs 
of anaemia. 
The biochemical characteristics in vitamin B | 2 deficiency include a comparable 
megaloblastic anaemia as in folate deficiency. Recent studies revealed that the clini­
cal symptoms of vitamin B ! 2 deficiency are much more diverse than previously 
believed. The serum vitamin B ! 2 radioassay is an useful screening test for vitamin 
В |2 deficiency. However, not all patients with a low vitamin B ] 2 level demonstrate 
clinical symptoms of vitamin B ] 2 deficiency and not all patients with clinical symp­
toms show low vitamin B P levels. Additional tests for the determination of the 
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metabolic availability of vitamin В,
 2 are measurements ot methylmalonic acid and 
total homocysteine in blood and urine (Stabler et al , 1988, Allen el a l , 1990, Hall 
and Chu, 1990, Lindenbaum et al , 1990) The Schilling test is a method to diagnose 
vitamin B]2 malabsorption The patient receives orally radioactive vitamin B ] 2 
after the administration of 1 0 mg parenterally unlabelled vitamin B ( 2 The propor 
tion of the administered radioactivity excreted in the unne during the next 24 h pro­
vides an accurate measure of absorption of vitamin Bj2 (Bdbiorand Bunn 1980) 
The main treatment in vitamin B ! 2 deficiency is replacement therapy combined 
with specific therapy related to the underlying disorder In the case of a malabsorp­
tion disorder the replacement should be administered parenterally or intramus­
cularly Oral treatment of hydroxocobalamin is possible, however at doses of 
300 mg to 1000 mg per day 
Genetic disorders of vitamin B J 2 metabolism 
Genetic disorders affecting the absorption, transport and metabolism of vitamin 
В IT are rare Up to now eleven different inherited defects have been described 
(tables 2 7 and 2 9) Four of them affect absorption and transport and the other seven 
affect intracellular metabolism of the vitamin (Fenton and Rosenberg, 1989, Surtees 
and Leonard, 1990) All the malabsorption disturbances are autosomal recessively 
inherited intrinsic factor deficiency, Immerslund-Grasbeck syndrome (ι e , entero 
cyte vitamin В 1 2 malabsorption or intrinsic factor receptor deficiency), transcobala 
min-2 deficiency, R binder (transcobalamin-1 ) deficiency 
Intiinsic factor clefîcienc\ A very rare inherited condition in which an abnormal 
intrinsic factor is secreted by a histologically normal stomach will cause clinical 
symptoms of a vitamin B ] 2 deficiency in infancy or early childhood after depletion 
of the fetal hepatic vitamin B ] 2 stores (figure 2 7, no 1, and table 2 9) (Babior and 
Bunn, 1980) After a normal first year of life these children develop anorexia, irrita-
bility, failure to thrive muscular weakness, drowsiness, developmental retardation, 
stomatitis, atrophic glossitis, signs ot peripheral neuropathy and often there is hepa-
Table2 9 Summary ol biochemical findings in inborn errors ol vitamin B12 absorption or transport 
(modified from Surtees and Leonard 1990) 
Biochemical 
characteristics 
Vitamin Bp serum 
Folate serum 
Homocystinuna 
Methylmalonic aciduria 
Vitamin Bp malabsorption 
Intrinsic tactor 
deficiency 
Low 
Normal 
Moderate 
Moderate 
Present 
Immersi und Grasbeck 
syndrome 
Low 
Normal 
Moderate 
Moderate 
Present 
Transcobalamin 2 
deficiency 
Normal 
Normal 
Mild 
Mild 
Present/Absent 
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tosplenomegaly Biochemical characteristics are megaloblastic anaemia, low serum 
vitamin B ) 2 levels, moderate methylmalonic aciduria and homocystinuna (Fenton 
and Rosenberg, 1989) Pernicious anaemia, probably caused by an autoimmune 
reaction against gastric parietal cells, is the most common cause of acquired vitamin 
Β ρ deficiency due to decreased intrinsic factor secretion 
Immerslund-Grasbeck syndrome This selective vitamin B 1 2 malabsorption/ 
transport disorder is most common among Finnish or Jewish (North Africa) inbred 
populations (figure 2 7, no 2, and table 2 9) ( Surtees and Leonard, 1990) The onset 
of clinical symptoms is between the ages of 1 and 15 years as in primary intrinsic 
factor deficiency Symptoms are predominantly gastrointestinal and developmental 
delay Peripheral neuropathy and myelopathy are seen infrequently Biochemical 
characteristics are megaloblastic anaemia, low serum vitamin B | 2 levels, moderate 
methylmalonic aciduria and homocystinuna The majority of patients have or deve 
lop proteinuria with or without renal tract abnormalities 
Transcobalamin-2 deficiency The clinical symptoms of this disease are manifest 
within the first months of lite and include gastrointestinal symptoms, failure to 
thrive and severe weakness (figure 2 7, no 3, and table 2 9) (Surtees and Leonard, 
1990, Fenton and Rosenberg, 1989) Six to 15 months after the onset, symptoms 
such as peripheral neuropathy, myelopathy, encephalopathy, and especially deve­
lopmental retardation can occur Biochemical characteristics are megaloblastic 
anaemia, pancytopenia, and immune defects Serum vitamin B ) 2 levels are normal, 
or nearly so, in these patients, reflecting the fact that most serum cobalamin is car­
ried by transcobalamin-1 and other R-binders Serum and tissue folate are usually 
normal Methylmalonic acid and homocysteine levels in urine are slightly in­
creased 
R-binder deficiency This is a very rare disease and has been described only in 
adults with hemoglobinopathy or neurological disease with low serum vitamin B 1 2 
but normal transcobalamin 2 levels (figure 2 7) It is of interest that the abnormality 
may be more common in non-Caucasian populations (Cooper and Rosenblatt, 1987, 
Fenton and Rosenberg, 1989, Surtees and Leonard, 1990) 
The major treatment for each of these disorders has been administration of 
pharmacologic doses of vitamin В,
 2, either cyanocobalamin or hydroxocobalamin, 
usually administered by injection, with or without folate therapy 
Cellular utilization defects of vitamin B 1 2 are due to an inability to generate 
either methylcobalamin or/and adenosylcobalamin This results generally in a clini­
cally more severe metabolic disease with much higher methylmalonic acid and 
homocysteine concentrations in blood and urine than in the previous described 
malabsorption disorders They include cobalamin A and B, cobalamin E and G, and 
cobalamin С and D and F disease (table 2 7) (see also paragraph 2 3 Folic Acid, 
' Genetic disorders of folate metabolism" 
Cobalamin A and В In cobalamin A and В disease a defect is only present in ade-
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nosylcobalamin synthesis (figure 2.7. no. 8 and no. 9) (Surtees and Leonard. 1990: 
Cooper and Rosenblatt, 1987). Clinical symptoms present in approximately half of 
the patients in the neonatal period and the rest during infancy. Symptoms include 
failure to thrive, developmental retardation, acute encephalopathy, vomiting and 
hypotonia, which are all related to the accumulation of methylmalonic acid. 
Biochemical characteristics are normal serum total vitamin B ] 2 levels, massive 
methylmalonic acid excretion in urine, and no hyperhomocystcinaemia. Marrow 
failure may produce pancytopenia. Patients with cobalamin A and В disease are 
beneficially treated with cyanocobalamin or hydroxocobalamin and dietary protein 
limitation. Distinguishing СЫ A and В is only possible by biochemical studies on 
cultured fibroblasts. 
Cobalamin E and G disease: This rare group of inborn errors of intracellular uti­
lization of vitamin B ] 2 is caused by reduced activity of methionine synthase alone 
due to methylcobalamin deficiency and leading to homocystinuria with hypo-
methionaemia (figure 2.7. no. 6 and no. 7) (Surtees and Leonard. 1990; Fenton and 
Rosenberg, 1989). The onset is usually before the age of 6 months and the children 
show developmental delay with hypotonia and failure to thrive. The biochemical 
symptoms are megaloblastic anaemia, normal serum total vitamin B | 2 levels and 
normal serum and tissue folate concentrations. Treatment with pharmacologic 
doses of vitamin B 1 2 seems to be beneficial. The defects involved are not known, 
but appear to involve the reducing system necessary to maintain the methylcobala­
min methionine synthase complex in its active reduced state. Cobalamin E and G 
can be distinguished by biochemical studies on cultured fibroblasts. 
Cobalamin С and D and F disease: The precise defect in cobalamin С and D 
patients is not yet known, but involves an early step in the intracellular metabolism 
of vitamin B p (figure 2.7, no. 5) (Fenton and Rosenblatt, 1989; Surtees and 
Leonard. 1990). Cobalamin С disease shows clinical heterogeneity with infantile 
onset and late onset forms, and cobalamin D becomes manifest much later. There is 
some evidence in the largest cobalamin С group of fetal disease with intrauterine 
growth retardation in one baby and microcephaly in four others. Clinical symptoms 
include failure to thrive, developmental retardation, prominent neurological mani­
festations and megaloblastic anaemia. A few patients also have had retinal degene­
ration and other ophthalmologic changes. In older children seizures, ataxia and 
pyramidal signs may become evident. The activity of methionine synthase as well 
as methylmalonyl-CoA mutase seems to be decreased in patients with such disor­
der. One patient with cobalamin F has been described with only mild methylmalonic 
acid concentrations in blood (figure 2.7, no. 4). The defect in cobalamin F appears to 
be in the transport mechanism of vitamin В 1 2 over the lysosomal membrane into the 
cytosol. Biochemical characteristics are normal or raised levels of serum total coba­
lamin and folate. Methylmalonic aciduria and homocystinuria in these children are 
distinctly less severe than in those with isolated methylmalonyl-CoA mutase de­
ficiency. 
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Neural-tube defects 
During pregnancy serum vitamin В
 i2 levels fall progressively. Factors thought to 
be involved are haemodilution and active transfer to the fetus (Kaminetzky et al., 
1974; Shojania 1984). However, little is known about the supply of vitamin B 1 2 to 
the developing embryo during the first weeks of pregnancy when the placenta is 
absent. 
Direct associations between NTDs and vitamin Β ρ are yet not as conclusive as 
those with folate. Schorah el al. ( 1980) reported decreased serum vitamin B 1 2 levels 
of three mothers with anencephalic fetuses as compared with controls. NTD affec­
ted children born to women with gastric bypass operations for morbid obesity have 
been reported (Haddow et al., 1986). In addition, subnormal vitamin B 1 2 levels and 
a borderline low-folate level due to malabsorption in the pregnant or non-pregnant 
state have been reported in relation to a NTD pregnancy (Martin et al., 1988). The 
variation in the level of transcobalamin-2 is probably genetically determined. To 
identify biochemical components of the genetic predisposition to NTDs, 79 preg­
nant women who previously delivered of an infant with a NTD and 158 pregnant 
control mothers were subjected to amniocentesis (Magnus et al., 1991). The con­
centrations of transcobalamin-1 and lranscobalamin-2 in amniotic fluid were eleva­
ted in the NTD group. Gardiki-Kouidou and Seller (1988) confirmed these findings 
and proposed that the genetic predisposition to NTDs could partly reside in a distur­
bance of the production, tiansport or metabolism of vitamin B [ 2 . They determined 
lower levels of vitamin В | 2 in midtrimester amniotic fluid of fetuses with a NTD or" 
omphalocele, as well as in those mothers who had had a NTD infant in a previous 
pregnancy when compared to healthy controls. Levels ol the transcobalamins and 
the unsaturated vitamin В
 ] 2 binding capacity were abnormally elevated in the amni­
otic fluid of fetuses with a malformation and also of normal fetuses with a previous 
NTD sibling. This is in line with a recently reported study, in which significant 
lower vitamin B ) 2 levels in amniotic fluid were determined in pregnancies with 
NTDs as compared to pregnancies with normal outcome (Economides et al.. 1992) 
2.5 HOMOCYSTEINE 
Homocysteine metabolism 
The essential amino acid methionine is converted to S-adenosylmethionine by 
methionine adenosyltransterase (EC 2.5 1.6). S-Adenosylmethionine is the ulti­
mate methyl donor in the body. After methyl transfer S-adenosylhomocysteine is 
formed, which acts as a strong inhibitor of most methyltransferases (figure 2.8). 
S-Adenosylhomocysteine is reversibly hydrolysed to homocysteine and adenosine. 
Homocysteine is either remethylated to methionine or irreversibly transsulphurated 
to cystathionine and cysteine respectively (Muddetal., 1989). The remethylation of 
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Figure 2.8 Homocysteine metabolism in man (modified from Boers 1985b) 
homocysteine to methionine is catalyzed by the enzyme 5-methyl-THF-homocys-
teine methyltransferase (methionine synthase, EC 2.1.1.13) or by betainehomocys-
teine methyltransferase (EC 2.1.1.5). Methionine synthase requires 5-methyl-THF 
as a methyl donor and methylcobalamin as a methylcarrier. The irreversible conver­
sion of homocysteine into cystathionine is catalyzed by the pyridoxine-dependent 
enzyme cystathionine synthase. Cystathionine is converted to cysteine and other 
derivatives of sulphur metabolism (taurine, sulphite and sulphate). 
The methyl groups delivered by S-adenosylmethionine are necessary for DNA 
methylation. S-Adenosylmethionine is an important regulator of homocysteine 
metabolism. It inhibits 5,10-methylene-THF reductase and stimulates cystathionine 
synthase. A methionine deficiency results in a decrease of the concentration of S-
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adenosylmethionine through which the remethylation of homocysteine to methio-
nine is enhanced, and the transsulphuration of homocysteine to cystathionine and 
cysteine is decreased (Finkelstein 1990) Both will lead to a preservation oí methio-
nine 
Hyperhomocysteinaemia 
Defective transsulphuration as well as remethylation disorders will result in 
increased blood and urine levels of homocysteine Therefore, both hyperhomocys-
teinaemia and homocystinuna are used to describe elevated levels in respectively 
blood and urine 
Transsulphuration dejects 
Classic homocystinuna is the homozygous form of the autosomal recessively 
inherited cystathionine synthase deficiency Biochemical features are hypermethio-
ninaemia, homocystinuna, hyperhomocysteinaemia and hypocystinaemia Clinical 
characteristics are premature atherosclerosis and thrombosis, ectopia lentis, bone 
deformities as scoliosis, marfanoid features, and mental retardation (Mudd et al , 
1989) The birth prevalence of heterozygosity for cystathionine synthase deficiency 
varies between several countries trom 1 70 to 1 200 (Boeis et al , 1985a) 
Cystathionine synthase deficiency is characterized by a decreased enzyme activity 
in liver and cultured fibroblasts resulting in mild hyperhomocysteinaemia (Mudd 
1989) Hyperhomocysteinaemia may be a risk factor in the development of prema-
ture peripheral atherosclerosis, ischemic cerebrovascular pathology and coronary 
vascular disease (Boers et al , 1985a, Malinow et al , 1989; Brattstiom et al , 1990, 
Clarke et al , 1991) 
Remethylation defects 
Over the past decade it has become apparent that an increase in the homocysteine 
level in plasma and urine without raised methionine levels could be caused either by 
insufficient folate availability in its active form 5-methyl-THF, or by a lack of 
methylcobalamin due to malnutrition, or by genetically determined defects in folate 
and vitamin B12 metabolism (Kang et al., 1987, Stabler et al , 1988, Brattstrom et 
al , 1988a, Rosenblatt 1989, Mudd et al., 1989). The causes of genetic disorders in 
folate and vitamin B ! 2 metabolism are described in paragraph 2 3 Folic acid, and 
paragraph 2 4 Vitamin В 1 2 
Patients with a defect in folate or vitamin B ! 2 metabolism are at risk of develo­
ping megaloblastic anaemia, psychiatric and neurologic abnormalities, mental 
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retaidation. and premature atherosclerosis and thrombosis The biochemical hall­
mark in contrast to classic homocystimma consists of low normal or decreased me­
thionine concentration in plasma. Acquired folate or vitamin B|i deficiency can 
iesult in the same biochemical and clinical features. 
Therapeutic ι eg i men s 
Treatment with high dose pyndoxine (vitamin B6) has a homocysteine lowering 
effect in about half the homozygotes with cystathionine synthase deficiency Their 
residual activity of the enzyme is probably enhanced by the high concentrations ot 
the colactor. Alternatively, the remelhylation of homocysteine into methionine in 
cystathionine synthase deficient patients can also be increased by high dose folate 
treatment (Hollowell et al . 1968, Morrow and Barness. 1972, Brattstiom et al., 
1985, Brattstiom et al , 1988b; Wilcken et al, 1988, Brattstrom et al, 1990) Other 
theiapeutic options in pyndoxine non-responsive homocystinuncs are the orai 
administration oí betaine, or choline to enhance the remethylation of homocysteine 
into methionine, or a methionine restiicted diet (Smohn et al., 1981; Perry et al., 
1968. Mudd 1989). 
A disorder in folate metabolism can be treated with folate and betaine. Patients 
with a defect in vitamin B12 metabolism are treated with high doses of cyano- or 
hydioxocobalamin. and with betaine to decrease homocysteine levels and to in-
crease methionine concentrations However, treatment for patients with both hyper-
homocysteinaemia and methylmalonic aciduria still has a very poor result. 
Homocysteine metabolism and hormones 
Mudd and Poole (1975) were the first to observe that the mean fasting levels of 
homocysteine-cysteine-mixed-disulphide were higher in normal men than in heal-
thy women. This has been confirmed by other workers (Wilcken and Gupta, 1979; 
Boers el al.. 1983a) Homocysteine levels in the tasting state and after standardized 
oial methionine loading in men but also in postmenopausal women were signifi-
cantly higher when compared to premenopausal women suggesting a unique effi-
ciency ot methionine handling in premenopausal women as a protection against 
homocysteine accumulation (Boers et al., 1983b; Brattstrom et al., 1985). However, 
Andersson et al. (1992a) showed significant differences in basal, not in afterload, 
plasma homocysteine values between men and women In addition, women might 
tiansaminate methionine by an alternative catabohc pathway al a higher rate com-
pared with young men (Blom el al., 1988) In summary, sex hormones seem to 
modulate serum homocysteine concentrations 
The preliminary data of Wong and Kang (1988) showed that women on oral con-
ti accpti ves had elevated plasma homocysteine levels. However, because decreased 
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levels oi folate, vilamin В12 and vitamin B6 have been lepoited with the use о I 01 al 
contraceptive therapy and dunng piegnancy it is dilhcult to assess whethu die 011 
gin of the el feet on homocysteine melabohsm is caused by the \1tam1n status or b\ 
hormonal influences (Rose 1966 Shane and Contiactor 1975 Mai tine/and Roe 
1977 Millet et al 1978. Shojania 1982 Shojania 1984 Mountiheld 198ö) The 
effect of oral conti aceptive use as well as the physiological fluctuation ol noi mone 
levels within the menstrual cycle on homocysteine metabolism needs luithei study 
Brattstiom et al (1992) studied the influence of oral low oestiogen containing con-
traceptives in women Although the oestrogen containing piepaiations decieased 
the serum levels ol folate and \1tam1n B)2 no signilicant diffeience in plasma total 
homocysteine concentration in the tasting stale and aflei loading could be de-
termined between women using oral contraceptives and age matched female con 
trois They also studied high-dose oestrogen tieated men with pioslalic caicinoma 
Within 4 weeks serum vitamin B P levels were significantly decieased without 
significant changes in fasting and allerload homocysteine levels Theiefoie these 
findings do not suppoit the hypothesis that the incieased caidiovasculai nsk in 
women on oial low oestiogen-containing conliaceptives and in oestiogen Heated 
men with piostatic caicinoma is a result of induced chionical h\pcihomocysiemae 
mia Howevei it is not excluded that during the use ol oral sub-50 conliaceplives 
cyclically lecuuent penods of hyperhomocysteinaemia occui and lead to tempoiaiy 
endothelial damage In our study descnbed in chaptei 5 we piovide evidence foi 
such a phenomenon 
An intriguing field ol investigation is the metabolism of homocysteine dunng 
pregnancy a period during which the concenti ations ol sex hoi moues aie mai kedly 
elevated It has been ìeported that in noimal pregnant women homocysteine meta-
bolism might be moie ellicient than in the non piegnant state (Kang et al 1986) 
Andeisson et al (1992b) reponed that serum total homocysteine was signihcantly 
decreased in the first tnmestei ol pregnancy In the second tiimestei homocysteine 
levels became maximal but were still lowei than in the non piegnant state wheie 
after the level remained stable thiough the lemainder ol piegnancy Within 2 4 days 
post pat turn plasma total homocysteine levels returned to noimal 
Several case-repoils detailing picgnancies in women with homocystinuria due to 
cystathionine synthase deficiency have been published These have been ïeviewed 
by Muddet al (1985) and some cases did have a pooi obstetric histoiy especially in 
the untreated group The outcome in mild to moderate hypcrhomocysteinaemic 
mothers is unknown 
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Chapter 3 
METHODOLOGY 
STUDY POPULATIONS 
The study concerning the impact of hormones on folate kinetics reported in chap­
ter 4 was conducted ι η 29 healthy women who took Marvelon®, an oral monophasic 
sub-50 contraceptive containing 30 μg of ethinyloestradiol and 150 μg of desoge-
strel per tablet, and in 13 healthy control women with regular menstrual cycles, who 
had never used oral contraceptives or had not done so for at least one year prior to 
the investigation The study described in chapter 5 concerning the impact of sex hor­
mones on homocysteine metabolism comprised 11 healthy oral sub-50 contracep­
tive users out ot the 29 subjects who also participated in the atorementioned study ot 
chapter 4 The control group consisted of 15 healthy controls other than those 
described in chapter 4 
The studies as described in chapters 6 and 9 were conducted in a control group 
and in women who previously had given birth to an infant with a NTD (chapter 6), 
and women who experienced recurrent spontaneous abortion or abruptio placentae 
(chapter 9) The 15 control women of the study described in chapter 5 were all inclu­
ded in the control group of the studies described in chapters 6 and 9 
The groups studied in the other chapters (chapters 7 and 8) were all different, and 
there was no overlap of women between these study populations 
METHIONINE LOADING TEST 
At 900 a m , after an overnight fast and the acquisition of a basal blood sample, 
an oral dose of L-methionine, 0 1 g (0 7 mmol) per kilogram body weight was admi­
nistered in 200 mL orange juice. During the test period, the women ingested a me-
thionine-restncted diet which provided a total of 0 014 g of methionine A second 
blood specimen was obtained six hours after the methionine loading The methio­
nine loading tests were performed in women without any evidence of gastro­
intestinal or endocrine disorder, dietary restrictions, and who had not used within 
three months of the study any vitamin preparation, contraceptive, or other phar­
macologic agent 
Methionine intolerance was defined as the total plasma or serum homocysteine 
concentration in the second sample exceeding the mean value plus two times the 
standard deviation for the second sample of the control group. 
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CYSTATHIONINE SYNTHASE ACTIVITY 
Contiol skin tibioblasts wcie obtained hom 8 healthy controls and 4 parents of 
childien with a disease not iclaied to homocysteine metabolism Fibroblasts weie 
also obtained hom 9 obligate heteiozygolcs foi cystathionine synthase deficiency, 
ι e , paients of established homozygotes foi cystathionine synthase deficiency The 
fibroblasts were giown just to confluence in EMEM (GYBCO) with non-essential 
amino acids. \0c/< letal calf seium and antibiotics Cells were washed with PBS. har­
vested by using trypsin solution (0 25% w/v). washed three limes with cold PBS and 
the cell pellet was stoied at -80°C until analysis 
The cystathionine synthase activity was measured accoiding to Fowlei et al 
( 1978) with some minoi modilicalions (Boers et al . 1985c) In shoit, the cell pellet 
was suspended in 250 μ ι 50 niM potassium phosphate and 0 \ch Lubrol. pH= 7 4. 
30 minutes 0°C After centnfugation. 10 minutes at 10000 χ g, the supernatant was 
used foi the assay The assay, mixtuie contained 0 1 M Tris HCl. 8 niM senne. 2 5 
μ Ο L-[U-I4CJ senne (170 mCi/mmol). 15 mM/L homocysteine. I niM pyndoxal 
phosphate.and50μιlibioblastssupernatant, total volume 100μί.ρΗ=8 6 Alter5 
minutes preincubation at 37°C the incubation was started by addition ol L-homo-
cysteine Aftei 4 houis incubation at 37°C. a 15 μ ι aliquot ol the assay mixture was 
applied to Whatman 3 mm chromatography paper. 46 χ 2 5 cm Sepaiation of 
[ l 4C]senne hom [l4CJcystathionine was achieved by descending chiomatogiaphy 
in isopropanol H-iO lormic aud= 80 20 6 for 40 hours The position correspon­
ding lo cystathionine was cut into snips and then ladioactivily was measured The 
activity lor cystathionine synthase was expiessed as ninol cystathionine/hourmg of 
piotein Protein was mcasuied accoiding to Lowiy et al (1951) 
THE SAMPLING AND HANDLING OF BLOOD 
Anlccubital venous blood samples weie taken alter 15-30 minutes rest Blood tor 
measurements of vitamins, homocysteine, methionine hacmatology. hormones, 
liver and renal function paiameters was diawn in 10 niL 'Corvac' vacutamer glass 
lubes (Monoject. Sherwood Medical, no 8881-302015) and 4 mL EDTA vacuum 
glass tubes (Becton Dickinson, no 606452) and 10 mL hepanmzed vacutamer 
lubes of 10 mL (Monojecl. Sheiwood Medical, no 8881-321759). respectively 
Within 30 minutes aftei collection blood for the measurement ol total homocys­
teine in serum and plasma (Iree plus piotein-bound)and vitamins was centilfuged at 
3000 χ g for 10 minutes The plasma was separated and immediately stored at-20°C 
until analysis, which wasperloimed within 3 months al 1er collection 
The handling of samples of ovarian folhculai fluid (chapter 7) and amniotic fluid 
samples (chapter 8) was similar to that of blood 
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ANALYTICAL METHODS 
Haematology and urinary creatinine 
The venous haematocnt was measured by the microhacmatocnt method accoi 
ding to standard laboratory procedures (Tietz 1987) 
Mean cell volume (MCV) was measured by laser light-scattering of diflraction 
pattern after pretreatment with SDS (Technicon H-1 J) (Tietz 1987) 
The determination of creatinine in blood and urine is based on the Jatfe reaction 
The method comprises the formation of a red colour by reaction ol creatinine with 
picrate in an alkaline solution and the developed colour is measured spectiophoto 
metrically at 490 nm The results ot lolate in urine were expressed as nmol excie 
ted/mmol of creatinine The lattei method was used as acheck tor adequacy ol urine 
collection 
Hormones 
The levels of 17ß oestiadiol (pmol/L) and progesteione (nmol/L) in serum weie 
measured with the specific charcoal radio(immune)assay as described by Thomas et 
al (1977) The 17IJ-oestradiol assay cross reacted only with oestrone foi I 07c 
whereas all other steroids tested showed cross-ieactions ot <\7c The minimum 
detectable concentrations ot 17B oestradiol and progesterone were respectively 75 
pmol/L and 1 3 nmol/L The precision in terms ot wilhin-assay and between-assay 
coefficients of variation for means ot duplicate determinations were in the case ot 
17ß-oestradiol 4 37c and 7 97c and in the case ot progesterone respectively 4 1% 
and 9 1% 
Serum TSH was measured by time-resolved immunefluoroirielric assay (DbLFIA 
Wallac Oy Turku Finland) The detection limit of this assay is 0 03 mU/L. 
between- assay coelficient ot variation al 1 17 mU/L is 4 07c, within-assay coeffi 
cient of variation is 2 97c The 957c relerence range foi healthy individuals is 
0 4 - 4 0 mU/L 
Serum total T4 was measured by two different radioimmunoassays Autopak/ 
Micromedic Systems (Los Angeles U S A ) and Amerlex M (Kodak Amersham 
Amersham U К ) Between-assay and within assay coefficients ot variation are 
3 57c and 37c at a level ot 104 nmol/L The reference ι ange for healthy individuals is 
65- 130 nmol/L 
Serum tree T 4 was measured by means ol an antibody-binding assay (Byk 
Sangtec Dietzenbach, Germany) Between-assay and within-assay coefficients of 
variation at a level ot 15 9 pmol/L are 6 17c and 4 37c The reference range for heal 
thy individuals is 9 - 18 pmol/L 
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Liver and renal function parameters 
Alkaline phosphatase (EC 3 13 1), aspartate aminotransferase (AST) (EC 
2 6 11) and alanine aminotransferase (ALT) (EC 2 6 12) were routinely measured 
by IFCC recommendations at 30°C as previously described (Tietz 1987) 
Urea was measured according to Urease-GLDH method (Tietz 1987) The Uncase-
PAP method was used to measure uric acid (Tietz 1987) 
Radioassays 
Folate and \ itamin Bj2 
Concentrations of folate and vitamin B[2 were determined in serum, urine (chap 
ter 4), ovarian follicular fluid (chapter 7) and amniotic fluid (chapter 8) by using the 
Dualcount SPB (Solid Phase Boil) Radioassay (Diagnostic Products Corporation, 
Los Angeles, CA, U S A ) The method includes a heat denaturation step oí endoge-
nous protein (15 minutes at 100°C pH= 9 3) of the unknown samples and the cali-
brators (zero dose standard and six calibrators containing between 40-1800 pmol 
vitamin B ) 2 and 1-55 nmol folate per liter ol a protein matrix) At this stage the dual 
label tracer solution (cobalt 57 vitamin B [ 2 and iodine-125 folate) was added It 
contained dithiothreitol and potassium cyanide (pH= 9 3) to release the vitamin B | 2 
and folate in the sample from carrier proteins Next, a suspension of the solid phase 
binders for vitamin В ¡2 and folate (purified hog intrinsic factor, and ß-lactoglobulin, 
respectively, coated onto microtrystalhne cellulose particles) was added and incu 
bated for 60 minutes at room temperature and pH= 9 3 At this pH, intrinsic factor is 
fully active and the folate binder has equal affinity for 5 methyl-THF and its stable 
form, pteroylglutamic acid (also used as the calibrator preparation) Following 
bound-free separation by centnfuging (15 minutes at 3000 χ g) and decanting the 
supernate, the radioactivity of the bound (precipitate) fraction was counted and the 
quantitation of the analytes was performed using the logit log calculation facilities 
present in this laboratory (Ria Cale, Wallac Oy, Turku, Finland) 
Red cell folate concentrations were calculated from folate measurements in hepa-
nnized blood hemolysate and plasma Hemolysates were made in three dilutions in 
assay butter (21x, lOx and 5x) to which 1% ascorbic acid was added The calcula­
tion was done according to the equation 
RCF = L D F x R - S ( l - H ) ] / H where 
RCF = red cell folate level (nmol/L), 
R = hemolysate folate level (nmol/L), 
DF = dilution factor of hemolysate (ι e , 21 ), 
S = plasma folate level (nmol/L), 
H = haematocnt (L/L) 
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The minimum detectable concentration of red cell folate thus calculated was 48 
nmol/L since the lowest detectable plasma level is 1 1 nmol folate/L and the highest 
haematocnt found was 0 48 The minimum detectable serum concentration for vita­
min В l 2 was 40 pmol/L as calculated at the B/BQ response level of Ü 90 
Assay precision in terms of intra and inter-assay variabilities for means of dupli-
cate determinations was calculated from 24 consecutive assay runs with two diffe-
rent plasma pools At mean pool levels of 20 and 40 nmol of folate per liter and of 
540 and 800pmol of vitamin B ) 2 per liter the coefficients of variation for intra and 
inter-assay precision were always <5%, and <10%, respectively, with each of the 
two vitamins 
HPLC-analysis 
Vitamin Bñ 
The determination of vitamin B6 as pyndoxal-5 -phosphate in whole blood, ova-
rian follicular fluid (chapter 7) and amniotic fluid (chapter 8) was performed with 
the HPLC technique first described by Schrijver et al (1981) In brief, the procedure 
involved the following steps which included several modifications concerning the 
denaturation of whole blood and fluids, the mobile phase and the HPLC column 
used To 1 mL of hepannized blood and fluids 1 mL of 1 2 M perchloric acid 
(HCIO4) was added and the supernatant was collected after centnfugation at 1000 χ 
g for 10 minutes To 0 5 mL of the supernatant 0 05 mL of a 4 4 M potassium hy­
droxide (KOH) solution was added and the supernatant was collected after centnfu­
gation (10 minutes at 1000 χ g) With an automated sampler (Wisp 710B, Waters 
Associates, Millipore Corporation, Milford, MA, U S A ) 0 2 mL of the supernatant 
was injected on a Microbondapak CI 8 Radial Pak 8 mm column with a Guard Pak 
pre-column (Waters) equipped to an automatic HPLC pump (Model 590, Waters) 
The mobile phase comprised a 0 025 M citrate buffer pH= 2 7 containing 20 mg/L 
of hexane sulphonate (FSA Laboratory Supplies, Loughborough. England) Post-
column denvatization according to Schrijver et al ( 1981) was performed with semi-
carbazide reagent to obtain the pyndoxal-5'-phosphate semicarbazone By using 
wavelengths for excitation and emission of 367 nm and 478 nm the fluorescence 
was determined with a Shimadzu RF-5000 fluorospectrophotometer (Shimadzu 
Corporation, Tokyo, Japan) equipped with a 12 μ ι HPLC Cell and connected to an 
integrator (Shimadzu С R5A) for calculation of the whole blood concentrations We 
established linearity of the fluorescence response of the pyndoxal-5 -phosphate 
standards between 4 and 400 nmol/L For routine purposes we processed a working 
standard of approximately 50 nmol/L pyndoxal-5'-phosphate after each fourth or 
fifth whole blood sample being processed in duplicate The minimum detectable 
concentration is 2 nmol/L at a fluorescence response of signal-to-noise ratio of at 
least three The precision of the technique in terms of the intra assay and inter-assay 
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variation as calculated from a whole blood and fluid control stored in separate tubes 
at -20°C until use was \.bc/c (20 replicate determinations, mean concentration 52 
nmol/L) and 5.5% (15 determinations on several days, mean concentration 53 
nmol/L). respectively. 
The total analysis time of a whole blood or fluid sample takes approximately one 
hour and a half. With the equipment described, theoretically up to 20 samples can be 
processed during one working day, or 40 determinations within 24 hours. 
Total homocysteine 
Total homocysteine (free plus protein-bound) concentrations in plasma (chapters 
6 and 8) and amniotic fluid (chapter 8) was measured by an automated HPLC 
method with reverse phase separation and fluorescent detection (Gilson 232-401 
sample processor, Spectra Physics 8800 solvent delivery system and Spectra 
Physics LC 304 fluoromcler), essentially according to Fiskerstrand et al. (1993). 
The handling of amniotic fluid samples prior to HPLC analysis was similar to that of 
plasma. The blood samples were taken in the lasting state, and six hours after met­
hionine loading. 
The total homocysteine determination by this method is based on complete 
reduction of all homocysteine disulfide bounds in plasma by sodiumborohydride 
and dithioerythritol. After derealization by monobromobimane the resulting homo-
cysteine-monobromobimane complex is separated from interfering substances by 
reverse phase chromatography. For accurate homocysteine determination plasma 
must be separated from the red cells within 30 minutes of collection and stored at -
20°C. 
The following derivatization process was used: 30 μ ι plasma was mixed with 30 
μ ι of4 mol/L NaBH4 and 333 mL/L DMSO, 10 μ ι of 2 mmol/L EDTA and 1.65 
mmol/L DTE and 0.1 mmol/L cysteamine (as an external standard), 10 μ]^ of 1-
octanol, and 20 μ]^ of 1.8 mol/L HCl. After 3 minutes (reduction of disulfides), 100 
μ ι of 1.5 mol/L ethyImorpholine buffer, 400 μΐ, of H 2 0 , and 20 μΐ. of 0.025 mol/L 
monobromobimane were added. The derivatization with monobromobimane was 
terminated after 3 minutesby adding 40 μ ι of glacial acetic acid. 
Chromatography: a 20 μL· aliquot of the derivatized sample was injected on a 
supelcosil LC-18 column (150 χ 4.6 mm, 3 μπι, Supelco), equilibrated with 30 
mmol/L ammonium nitrate, 40 mmol/L ammonium formate and 5 mmol/L tetrabu-
tylammoniumhydrogen sufate, pH= 3.4. Four minutes after injection homocysteine 
was eluted of the column with a gradient of 8%- to 11 % acetonitrile with a flow rate 
of I mL/minute. The retention time of homocysteine was about 12 minutes. 
Recovery of homocysteine added to plasma is about 95%. The intra-assay CV is 
2.1 % and the inter-assay CV is 5.2%. 
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Amino acid analysis 
Total Iwniocì steine 
In contrast to the methodology used in the other studies (chapters 6 and 8) total 
homocysteine (free plus protein-bound) in serum (chapters 5. 7 and 9) and ovarian 
follicular fluid (chapter 7) was measured using an amino acid analyser The hand-
ling of follicular fluid prior to amino acid analysis was similar to that of serum The 
concentrations of total homocysteine in serum and plasma are not significantly dif-
ferent (Fiskerstiand el al 1993) 
The following denvatization procedure was applied To 0 3 mL thawed plasma 
0 3 mL dilhiothreitol (40 mM pH= 9 0) was added and mixed After incubation for 
10 minutes at room temperature the mixture was deproteinized by adding 0 3 mL of 
sulphosalcyhc acid (259r w\v) containing norleucine (306 μΜ) as an external stan­
dard After vortexing the mixture was kept on ice for 10 minutes and centnfuged at 
3500 χ g for 10 minutes The supernatant was liltrated through a 0 45 μηι filter 
Samples were analyzed on an automatic amino acid analyzer (Pharmacia LKB 
Alpha-Plus) A volume ot 140 [iL· was injected on the column Separation ol the 
amino acids was performed by changing temperature of the column and the concen 
tration and pH ot the lithiumcitrale buffer An ion exchanged column (length 240 
mm, I D 4 6 mm and a particle size ot 6 μηι) was used Not only homocysteine was 
eluted but also the acid and neutral amino acids The programme was changed in 
favour of the separation ol homocysteine and methionine and the external standaid 
norleucine After post-column denvatization with ninhydnn, the absorption intensi 
ties were measured by a spectrototometer with an extinction at 570 nm The detector 
signal was recorded and the peak area was quantified with a Spectra-Physics in 
tegrator (Chromjet SP4400) The intra assay CV tor homocysteine is 3 3% and the 
inter assay CV is 3 2% 
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Chapter 4 
ORAL SUB-50 CONTRACEPTIVES AFFECT 
FOLATE KINETICS* 
INTRODUCTION 
There is much controversy about the influence of oral contraceptive use on the 
serum concentiations and kinetics of iolate, vitamin В
 l2
 a n d i r o n status (Wertaliket 
al, 1972, Prasad et al , 1975, Shojania 1982 Rivera et al, 1983 Mountifield 1986, 
Mooij et al, 1992) Several investigations have shown that oral contraceptives con 
taming 50 μg of oestrogen or more cause a decrease of folate concentrations in 
serum and red cells (Shojania et al , 1968, Streiff 1970, Shojania et al , 1971, 
Martinez and Roe 1977. Hettiarachchy et al 1983) This effect could be due to 
either a decreased absorption of the natural folic acid polyglutamate form of folate, 
an increased turnover of folate due to hvei enzyme induction or altered renal hand­
ling (Burton 1967, Necheless and Snyder, 1970 Stieiff 1970, Shojania et al , 1975) 
Other workers, however, failed to confirm these observations (Paine et al , 1975, 
Mountitield 1986) These discordances of results could be due to different concen­
trations of oestrogen in the oral contraceptives (Heilmann 1979) Less information 
is available about the effect of oral contraceptives containing less than 50 μg of oes­
trogen 
Since studies suggest an association between a shortage of vitamins, in particular 
of folate, and the prevalence of NTDs. interest in vitamin delìciencies in the precon-
ceptional period and in early pregnancy has increased (Steegers-Theumssen et al , 
1993a) In view of the preconceptional status, the present study was performed to 
determine the consequences of long-term oral sub-50 contraceptive use in healthy 
lertile women on blood levels of folate before and after an oral test dose of folic acid 
monoglutamate and on the excietion of folate in urine In addition, we also studied 
iron status to compare these data with those already available when using higher 
oestrogen-dosed oral contraceptive preparations 
" Steegers Theumsscn RPM RossumJMvan SteegersEAP Thomas CMG EskesTKAB Sub 50 oral 
contraceptives atleet folate kinetics Gynecol Obstel Invest in press 
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MATERIALS AND METHODS 
Study groups 
Fourty-two healthy volunteers were studied after informed consent was obtained. 
The group characteristics are presented in table 4.1. 
Table 4.1 Description of oral sub-50 contraceptive (OC) users (Group I) and controls (Group II); 
Results are presented as median values and the ranges are given in parentheses 
Group I Group II 
OC users Controls 
Number of women 29 13 
Age (years) 23(21,32) 25(22,28) 
Body mass-index (kg/m-) 22(19,31) 21(18,24) 
None of the participants had any clinical evidence of gastrointestinal disease or 
was restricted in her dietary intake. Neither folate-, iron-, vitamin В ] 2 supplements, 
nor any other medication had been used for at least three months prior to the study. 
At the time of study twenty-nine of the subjects (group I) were using the oral sub-50 
contraceptive Marvelon® (Organon, Oss, The Netherlands) for an average period of 
4.6 years (range 1-8 years). Thirteen women with regular menstrual cycles, who 
never had taken oral contraceptives (group II) were used as controls. Concentrations 
of 17ß-oestradiol and progesterone were measured in serum and information was 
obtained about the first day of the next menstrual period to verify in retrospect the 
accuracy of the 3 r d menstrual day of the cycle. Marvelon® is an oral monophasic 
contraceptive with a synthetic 'cycle' of 7 days without and 21 days with the use of 
one tablet. Each tablet contains 30 μg ethinyloestradiol and 150 μg desogestrel. All 
women were studied during the summer (May to September) on the third pillfree 
day (group I) or the third menstrual day (group II). 
Study design 
After an overnight fast, the subjects took 5.0 mg folic acid monoglutamate 
(Pharbita BV, Zaandam, The Netherlands) with 100 mL of water between 9:00 -
10:00 a.m. Venous blood samples were taken after 10 minutes rest at the time of 
ingestion of folic acid monoglutamate (t= 0) and 60, 120, and 210 minutes after­
wards. The folate concentrations were measured in serum and red cells within 3 
months after collection. All determinations, except for folate in serum, were only 
performed at t= 0. After having emptied their bladder on t= 0, the subjects collected 
urine from t= 0 onwards until the last venous puncture for the determination of 
folate excretion. Urine was collected in a bottle containing 8 g ascorbic acid. The 
folate excretion was expressed as μπιοί folate excreted per mol of creatinine. During 
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the test the subjects were allowed to drink mineral water and tea without milk with­
out restriction. 
Folate deficiency was defined as a concentration of serum folate lower than 5.0 
nmol/L, a red cell folate concentration lower than 295 nmol/L, and MCV higher 
than 96 fL. These values are comparable to those reported by Babior and Bunn 
(1980). 
Statistical analysis 
To compare the serial measurements of serum folate (= response curves) during 
the test between the two groups, the distribution-free statistical lest described by 
Koziol et al. (1981) was used. This test is suitable for the comparison between the 
median response curves of two or more groups. Differences between the two groups 
with regard to the median concentrations of folate in serum at each time point, and 
the median concentrations of red cell folate, serum vitamin B 1 2, iron, ferritin, TIBC 
and MCV, and folate excretion were analyzed with the Wilcoxon two-sample rank-
test. 
RESULTS 
The serum folate concentration profiles of the oral sub-50 contraceptive users 
(group I) and the controls (group II) are shown in table 4.2 and figure 4.1. 
At t= 0 no differences in the median concentrations of folate in serum were obser­
ved between the two groups. After the ingestion of folate, the median serum folate 
concentration increased in both groups. They were, however, consistently lower in 
group I, reaching a statistically significant difference at t= 210 minutes (P= 0.04). 
The response curves tended to be significantly different (Koziol P= 0.09). 
Table 4 2 Serum folate concentrations (nmol/L) in oral sub-50 contraceptive (OC) users (Group I) and 
controls (Group II) at the time ot ingestion of 5 0 mg folic acid monoglutamate (1= 0) and 60, 
120, and 210 minutes afterwards 
Time (minutes) 
0 
60 
120 
210 
Group I 
OC users 
median 
15 
220 
300 
260 
Scrum folate (nmol/L) 
(n=29) 
(range) 
( 6.32 ) 
(14,680) 
(21,710) 
(54,630) 
Group 11 
Controls ι 
median 
14 
330 
440 
400 
(n=13) 
(range) 
( 11. 37) 
( 25.720) 
(150,660) 
( 44,610) 
Ρ 
0.65 
0 79 
0 12 
0 04 
Ρ values indicate the differences between the median concentrations of the two groups, which are consi­
dered significant at P< 0 05 
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Figure 4.1 Median serum folate concentrations (nmol/L) in oral sub-50 contraceptive (OC) users 
(Group I. filled circles) and controls (Group II, open circles) at the time of ingestion of 
"\0mg lolic acid monoglutamate (t = 0) and 60, 120 en 210 minutes afterwards. 
Comparison between the median response curves (Koziol) revealed Ρ = 0 09: T P < 0 05 
The median (range) urinary folate excretion during the test was 1655 (48-1610) 
and 1350 (124-3330) μηιοί folate/mol creatinine in groups I and II, respectively, and 
showed no significant difference (P> 0.10). 
At t= 0 the median red cell folate concentrations were similar within groups I and 
II (table 4.3). The concentrations of serum iron and ferritin at t= 0 were not statisti­
cally different between group I and II. However, the median TIBC was significantly 
higher (P< 0.01) whereas the median vitamin B ] 2 concentration was significantly 
lower in oral contraceptive users compared with the control women (P< 0.05). 
Not any of the women out of group I and II appeared to be folate-deficient, and no 
difference between the two groups was found for MCV (table 4.3). 
DISCUSSION 
Previous investigations have shown lowering effects of oral contraceptives con­
taining more than 50 μg oestrogen on folate levels with and without the occurrence 
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Table 4 3 Vitamin and iron sums in oral sub-50 conlraceptivc (OC) users (Group 1) and conlroK 
(Group Шоп t=0. Results are median \alues. the ranges are gi\ en in parentheses 
Red cell Colale 
(nmol/L) 
Scrum vitamin В 12 
(pmol/L) 
Serum non 
(μιτιοΐ/ΐ.) 
Sei um ferritin 
(μπιοΙ/L) 
Т1ВС(цто1/и 
MCV(fL) 
Group 1 
OC-i 
434 
jseis (n=29) 
(300,840) 
240 
( 90. 
16 
(12. 
28 
( 5. 
75 
(54. 
90 
(78. 
330) 
34) 
140) 
90) 
95) 
Urou ρ II 
Contiols(n=n) 
432 
(350.840) 
280 
(150.490) 
15 
( 9. 
30 
( 6. 
56 
(45, 
90 
(78. 
29) 
82) 
75) 
95) 
Ρ 
N S 
P<0 05 
N S 
N S 
140 01 
N.S 
P-valucs indicate the significance ol dittciences between the median values of the tuo gioups 
N S - not significant 
of a folate deficiency (Slreiff 1970; Shojania et al.. 1968). The results of this study 
suggest that oral sub-50 contraceptives could have an impact on folate absorption 
without inducing a folate deficiency. After loading with folic acid monoglutamates 
the median concentration of folate in the serum of the oral contraceptive users com­
pared with the control women was decreased, reaching a significantly lower level at 
210 minutes. A possible explanation for this finding can be provided by discussion 
of the mechanism of the absorption process of folate. The absorption process is divi­
ded into two steps (Davis 1986). During the first step folic acid polyglutamates are 
converted to folic acid monoglutamates by intestinal conjugase. The second step 
includes absorption by active transport and diffusion. Because we used folic acid 
monoglutamates in our oral test, the first step is not investigated in our study. Thus, 
it seems logical to assume that the absorption process of the second step is influen­
ced by the oral sub-50 contraceptives used. However, this is in contradiction to pre­
vious studies that demonstrated attenuated absorption curves after oral folic acid 
polyglutamates but not after folic acid monoglutamates as used in our study 
(Necheless and Snyder, 1970; Strciff 1970; Shojania and Hornady. 1973). This 
requires further investigation. 
Although Shojania et al. (1975) discovered increased folate excretion in oral con­
traceptive users after intravenous pteroylmonoglutamic loading, the differences 
found in the serum profile of folate after loading between the oral contraceptive and 
58 
the control group in our study were not reflected in differences in urinary folate 
excretion This might be due to the short time of unne collection, ι e , 210 minutes 
after the test-dose of 5 0 mg of folic acid monoglutamate was given 
The TIBC was increased in the oral contraceptive group, which has previously 
been reported in women using oral sub-50 contraceptives (Rivera et al, 1983,Mooij 
et al, 1992) This might be due to increased protein synthesis by the liver induced by 
the oestrogen component of the oral contraceptive In contrast to the study of Mooij 
et al (1992) the concentration of serum iron was not significantly different between 
the two groups This is in agreement with the results of Liukko et al (1988), who 
also found no differences in serum iron concentrations in oral sub-50 contraceptive 
users Ferritin concentrations were not significantly different between the oral sub-
50 contraceptive users and controls However, Mooij et al (1992) showed a signifi­
cantly higher mean ferritin concentration in oral sub-50 contraceptive users than in 
controls, which might be due to differences in the duration of oral contraceptive use 
In agreement with previous studies with oral contraceptives containing either 
more or less than 50 μg of oestrogen, our study showed that serum vitamin В ]
 2 con 
centrations were significantly decreased in the oral sub-50 contraceptive group 
(Wertahk et al, 1972, Heilmann 1979, Shojania 1982, Moun ti field 1986, Mooij et 
al, 1991) This effect might be due to changes in the concentrations of transcobala-
min-1 and 2 and is usually not leading to vitamin B 1 2 deficiency 
These results suggest that oral sub-50 contraceptive therapy aifects folate kine­
tics without inducing a folate deficiency Therefore, no evidence was found that pre-
conceptional folate and vitamin В12 blood levels of women who were exposed for a 
long duration ot time to oral sub-50 contraceptives are detrimentally affected 
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Chapter 5 
EFFECTS OF ORAL SUB-50 CONTRACEPTIVE 
PREPARATIONS ON HOMOCYSTEINE METABOLISM* 
INTRODUCTION 
Homocystinuria is an autosomal recessively inherited disease involving the 
metabolism of the essential amino acid methionine, which results in vascular injury 
with the consequences of premature atherosclerosis and thromboembolism. These 
features are generally considered to be induced by accumulation of homocysteine in 
blood and tissues (Mudd et al., 1989). Sex hormones, and vitamin deficiencies are 
supposed to influence homocysteine metabolism (Wilcken and Gupta, 1979; Boers 
et al., 1983b; Stableretal., 1988). The involvement of folate, vitamin B,2 and B6 in 
the metabolism of homocysteine is described in chapter 2, paragraph 2.5 
Homocysteine, and shown in figure 2.8. 
Data from several epidemiologic studies indicated that women using oral con-
traceptives might show more frequently decreased vitamin levels, especially of 
folate, vitamin B12and vitamin B6(Rose 1971; Shojania 1982). In women suffering 
from homozygous homocystinuria, the occurrence of major and even fatal vascular 
complications has been reported shortly after starting with oral contraceptives 
(Grobe 1978; Boers et al., 1984). Apart from their inherent thrombotic risk oral con-
traceptives may induce depletion of cofactors involved in homocysteine metabo-
lism, resulting in further derangement of the hyperhomocysteinaemia (Maguire el 
al., 1979). The use of oral contraceptives in these patients, therefore, is generally 
considered to be contraindicated. Furthermore, it might be advisable to recommend 
heterozygous homocystinuric women not to take oral contraceptives for the same 
reasons, because carrier status for homocystinuria is supposedly also a risk factor 
for premature vascular disease (Boers et al., 1985a; Malinow et al., 1989; Clarke et 
al., 1991). 
It has been reported in normal persons that deficiencies of folate and vitamin B12 
can also lead to hyperhomocysteinaemia with levels comparable to those in hetero-
zygotes for homocystinuria (Brattström et al., 1988a). Based upon these observa-
tions, one can hypothesize that the occurrence of vascular events reported during the 
use of oral contraceptives may be induced, at least partially, by hyperhomocystein-
aemia caused by depressed levels of the aforementioned cofactors (Maguire et al., 
1979; Böttigeret al., 1980; Vessey 1982; Mishell 1989). 
* Steegers-Theunissen RPM, Boers GHJ, Steegers EAP. Tnjbels JMF, Thomas CMG, Eskes ТКАВ 
Effects of sub-50 oral contraceptives on homocysteine metabolism a preliminary study Contra­
ception 1992,45. 129-139 
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To explore further the interactions between the use of oral contraceptives, the 
levels of the substrate folate, the cofactors vitamin В
 ) 2 and B6, and homocysteine 
metabolism, we investigated the long-term effect of an oral monophasic sub-50 con­
traceptive in healthy young women as compared with a control group of women not 
using oral contraceptives We studied the fasting blood levels of total homocysteine, 
andot folate, vitamin В12 and B 6 on the 3rd and 21 st day of the pill cycle in users of 
oral contraceptives and in control subjects on the 3rd and 21 st day of the menstrual 
cycle To investigate episodic changes within one pill or menstrual cycle we com­
pared these parametei s on the 3rd day with those on the 21 st day in both groups 
MATERIALS AND METHODS 
Study groups 
Twenty-six healthy volunteers, who had not used any vitamin preparation or drug 
for at least 3 months prior to the investigation, were randomly recruited and studied 
after informed consent was obtained The experimental protocol was approved by 
the ethics committee on human expenmentation of the University Hospital St 
Radboud, Nijmegen Group I consisted of eleven women (mean age 26 years, range 
21-32) who took Maivelon®, an oral monophasic sub-50 contraceptive with a syn­
thetic cycle of 7 days without and 21 days with the use of one tablet, for a mean 
pei ïod of 3 7 years, range 1 -8 Each tablet contains 30 μg ethinyloestradiol and 150 
μg desogestrel Group II consisted of fifteen contiol subjects (mean age 29 years, 
range 24-38) who had never used oral contraceptives or had not done so tor at least 
one year prior to the investigation The first day of the pill cycle was defined as the 
first day alter the pill stop and the first day of the menstrual cycle was the first day of 
the menstrual period 
Study design 
All women were studied during one cycle in the low-hormonal phase of their pill 
or menstrual cycle, 1 e , on the 3rd pillfree day in group I, or on the 3rd menstrual day 
in group II, and in the high-hormonal phase of their pill or menstrual cycle as well, 
1 e , on the 14th pill day in group 1 or on the 21st day after the first day of the men­
strual period in group II In control women. 17ß oestradiol and progesterone con-
centrations were measured in serum and information was obtained about the first 
day of the next menstrual period to verify in retrospect the precision of the previous 
21st day of the menstrual cycle After an overnight fast and following 10 - 20 
minutes rest, venous blood samples were taken between 8 30 - 9 30 a m 
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Statistical analysis 
Results are expressed as median (range) Comparison between the two groups 
was performed by using Wilcoxon's two sample rank test and Wilcoxon's paired 
rank test to determine variances between and within groups 
RESULTS 
The median concentrations ol total homocysteine and vitamins in both groups are 
presented in table 5 1 and figure 5 1 On the low hormonal phase, ι e , day 3 of the 
cycle, the median fasting serum total homocysteine concentration of group I (oral 
contraceptive users), was significantly higher than of group II (control women) The 
median concentration of vitamin B 6 in whole blood appeared to be significantly 
lower in group I as compared with group II However, serum and red cell lolate and 
serum vitamin В
 i 2 concentrations were not different between the two groups 
During the high-hormonal phase, ι e , on day 21 of the cycle, the median fasting 
total homocysteine concentration of group I was not significantly different from that 
of group II Similarly, serum and red cell folate and vitamin В ] 2 concentrations did 
also not differ between group I and II In line with the observations made on the low-
hormonal phase of the cycle the median concentration of vitamin B 6 in whole blood 
on the high-hormonal phase was also significantly lower in group I than in group II 
Fasting total homocysteine and vitamin concentrations within each group, ι e , on 
the low- or high-hormonal phase of either one pill or one menstrual cycle, are also 
demonstrated in table 5 1 and figure 5 1 
Between the 3rd and 21st day of the pill cycle (group I) the median fasting total 
homocysteine concentration in serum and the serum vitamin B ] 2 concentrations 
differed significantly On the 3rd and 21 st day of the menstrual cycle (group II), the 
median serum vitamin B ] 2 concentration was significantly lower on the 21st pill 
day Between these days no significant differences were observed between the 
median fasting total homocysteine concentrations m serum, as well as the serum and 
red cell folate, and the vitamin B 6 concentrations 
DISCUSSION 
The present study shows that in long-term users of an oral monophasic sub-50 
contraceptive, the median homocysteine concentration in fasting serum is signifi­
cantly higher on the 3rd day of their cycle than in control women not taking oral 
contraceptives However, this difference was not significant in the high-hormonal 
phase, ι e , on the 21st day of the respective cycles In contrast with data from pre­
vious studies, we established no significantly lower concentrations of folate in fas­
ting serum or red cells and of vitamin B 1 2 in oral sub-50 contraceptive users when 
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Table 5 1 Median (range) concentrations of fasting total homocysteine in serum, folate in serum and red 
cells, vitamin B 6 as pyndoxal phosphate in whole blood and vitamin B ] 2 in serum of oral sub-
50 contraceptive (OC) users (Group 1) and control women (Group II) as measured on the 3rd 
and 21st day ot their cycles 
Total homocysteine 
serum (цтоІ/L) 
Significance 
Folate (nmol/L) 
serum 
Significance 
Folate (nmol/L) 
red cells 
Significance 
Vitamine B6 (nmol/L) 
whole blood 
Significance 
Vitamin B,
:
(pmol/L) 
serum 
Significance 
Day 
3 
21 
3 
21 
3 
21 
3 
21 
3 
21 
Group 1 
OC users 
(n=ll) 
11 (7.5.28) 
7 8(3.3.12) 
P<0.05 
13(6, 15) 
12(9,19) 
N.S 
430(190.630) 
440(310,650) 
N.S. 
43(32,56) 
43 (32.52) 
N.S 
220(160,320) 
200(140.330) 
P<0 05 
Group II 
Conlrols 
(n=15) 
66(3.2,17) 
6.4(2 9, 12) 
N S 
13(6,25) 
12(8,21) 
N.S 
480 (340,750) 
470 (330, 860) 
N S . 
47 (34,64) 
47 (36, 65) 
N.S. 
260(140,520) 
240 ( 93,420) 
P<0 01 
Significance 
P<0 01 
N S . 
N.S 
N.S 
N S 
N S 
P<0 05 
P<0 05 
N S 
N S 
N S not significant 
compared with control women either on the 3rd or 21 st day of the cycles (Shojania 
1982). However, on both days, the median fasting whole blood vitamin B6 concen­
tration was slightly, but significantly lower in oral contraceptive users. This is in line 
with the results of previous studies (Rose 1966; Coelingh Bennink and Schreurs, 
1974; Amatayakul et al., 1984). A possible explanation for the difference observed 
in serum homocysteine concentrations between both groups during the low-hor­
monal phase is this decrease in the oral contraceptive users of the median concentra­
tion of vitamin B6, the cofactor in the conversion of homocysteine to cystathionine. 
Notwithstanding a similar difference in vitamin B6 concentrations between oral 
contraceptive users and control women on the 21 st day of the cycles, the homocys­
teine concentrations in oral contraceptive users had decreased in this high-hormonal 
phase of the cycle and reached similar values to those measured in controls. In the 
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Figure 5 1 Median concentrations ot tasting total homocysteine (цгпоІ/L) in serum, serum and red cell 
folate (nmol/L), whole blood vitamin B 6 as pyridoxal phosphate (nmol/L) and serum vita­
min В,, (pmol/L) on the 3rd and 21st day of the pill or menstrual cycle in 11 oral sub-50 
contraceptive users (drawn line) and 15 control women (dotted line) 
Significance mthm groups (day 3 vs day 21) 
+ P< 0 05 
++ P<0 01 
Significance between groups (1 vs II, either day 3 or day 21 ) 
* P< 0 05 
** P<001 
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non-oral contraceptive user group, the individual homocysteine concentrations 
decreased in 11 out of the 15 women on the 21st day compared with those on the 3rd 
day of their cycle For the group, this difference was not statistically significant 
This despite slightly decreased concentrations of serum vitamin B,2 an important 
cofactor of homocysteine metabolism 
The decrease in homocysteine concentration in oral contraceptive users in the 
high-hormonal phase of the cycle as compared with the low hormonal one, cannot 
be explained by altered substrate or cofactor concentrations, since serum folate and 
vitamin Bh remain essentially unchanged and vitamin B 1 2 even decreases 
Therefore, one can hypothesize that a stimulating effect of the accumulated exo-
genously administered sex steroids of the oral contraceptive preparation on homo­
cysteine metabolism is responsible for the observed homocysteine lowering pheno­
menon Another explanation might be that inhibition of the synthesis of 
homocysteine from methionine occurs, as a result of the administration of sex ste­
roids 
We did not study subsequent cycles but all eleven oral contraceptive users except 
one showed a decline in homocysteine levels on the 21st day compared to the 3rd 
one Therefore, it seems reasonable to conclude that this effect ol oral sub-50 
contraceptives is an episodic phenomenon within one cycle, leaving the homocys­
teine levels in the low hormonal phases significantly higher than in non-users 
The concentrations of total homocysteine in fasting serum as measured in this 
study during the first phase of the artificial cycle with the use of oral sub-50 con­
traceptives are as high as determined in heterozygotes for homocystinuna (Ueland 
and Refsum, 1989, Brattstrom et al , 1990) Such carriership has been defined in 
recent years as a risk factor of premature vascular disease and also hyperhomocys-
teinaemia comparable with that in heterozygotes for homocystinuna has been asso­
ciated with an increased risk of premature atherosclerosis and venous thrombosis 
(Boers et al , 1985a, Malinow et al, 1989, Brattstrom et al, 1990, Clarke et al, 
1991 ) Deficiencies of folate or vitamin В12 are conditions which can be responsible 
for a rise in the homocysteine levels in normal persons up to concentrations in the 
same range as measured in heterozygotes for homocystinuna (Brattstrom et al , 
1988a, Stabler et a l , 1988, Hall and Chu, 1990) The cyclically recurrent penods of 
hyperhomocysleinaemia might be considered a predisposition to the occurrence of 
vascular events Such complications have been reported even when administering 
minimal doses of sex steroids and have up to the present been generally held to be 
caused by effects of the steroids upon haemostasis (Maguire et al, 1979, Vessey 
1982,Mishell 1989) 
The significant decrease in homocysteine levels at the end of the pill cycle is 
quite remarkable A direct positive effect of the sex steroids upon transsulphuration 
or remethylation of homocysteine might be hypothesized as a cause In favour of 
this hypothesis are the observations of significantly lower homocysteine levels in 
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the blood of premenopausal women compared to those in postmenopausal women 
and in men. both in the fasting state and after methionine loading (Wilcken and 
Gupta 1979, Boers et a l , 1983b, Ueland and Refsum, 1989). It has been speculated 
that this unique efficiency of homocysteine metabolism might account for the lower 
incidence of vascular disease in women in their reproductive life cycle (Boers et a l , 
1983b, Ueland and Refsum, 1989) Furthermore, in pregnant women the homocys-
teine levels are reportedly even more significantly lower than in non-pregnant 
young women (Kang et al , 1986) Therefore, the periodic decrease in the homocys-
teine levels in the high-hormonal phase of the cycle with an oral monophasic sub-50 
contraceptive as observed in this study might be caused by the accentuation of a 
direct, favourable effect of high levels of naturally occurring sex hormones, or their 
derivatives contained in oral contraceptives upon homocysteine metabolism 
In conclusion, long-term use of an oral sub-50 contraceptive is not expected to 
cause basal hyperhomocysteinaemia, through which the conceptus could be detri-
mentally affected during or soon after pill stop However, the possible role of sex 
hormones or analogues as modulators of the serum homocysteine levels seems to be 
very complex and the significance of the effects is an intriguing area for further 
investigation 
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PART III 
HOMOCYSTEINE METABOLISM AND ABNORMAL 
OBSTETRICAL OUTCOME 
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Chapter 6 
MATERNAL HYPERHOMOCYSTETNAEMIA: 
A RISK FACTOR FOR NEURAL-TUBE DEFECTS* 
INTRODUCTION 
Meningomyeloschisis, meningo(myelo)cele, encephalocele and anencephaly are 
serious birth defects due to a failure of closure of the neural-tube, and therefore, are 
designated as NTDs. The birth prevalence of NTDs differs between various 
geographical areas, ethnic races and seasons and is most common in low socioeco­
nomic classes (Laurence et al., 1968; Smithells et al., 1976). It is hypothesized that 
these midline defects, which develop during the third and fourth postconceptional 
week, are caused by the interference of a polygenically susceptible fetus with both 
maternal and environmental trigger influences (Carter 1974). As little can be done 
to modify the genetic factors, the primary prevention of these malformations would 
be dependent on the elimination of environmental teratogens. 
Epidemiological, clinical and teratological research data suggest that maternal 
nutrition is important and that vitamin deficiencies, especially of folate, play a role 
in the pathogenesis of NTDs (Carter 1974; Smithells et al., 1976; Scott et al., 199Θ; 
Steegers-Theunissen et al., 1993a). Folate is essential in DNA, tRNA and amino 
acid synthesis (Rosenblatt 1989). A lack of folate is a common condition usually 
caused by an intake lower than the metabolic demand and may relate to socioecono­
mic factors. This may be of particular importance during pregnancy when the meta­
bolic requirements may be increased but the availability of folate may be reduced 
due to changes in intestinal absorption and renal clearance (Shojama 1984). Under 
these circumstances a latent and previously asymptomatic genetic defect in folate 
metabolism may become manifest and result in a deficiency of 5-methyl-THF and 
other specific metabolic forms of the vitamin (Rosenblatt 1989). 
In mothers of infants with NTDs, low levels of red cell folate have been docu­
mented as compared with controls (Smithells et al., 1976). Data on the preventive 
effect of periconceptional administration of multivitamins or folate on the recur­
rence risk of NTDs have been conflicting (Steegers-Theunissen et al., 1993a). 
However, recently it has been pointed 'out that periconceptional folate treatment 
* Steegers-Theunissen RPM, Boers GHJ. Tnjbels JMF, Eskes TKAB Neural-tube detects and de­
rangement of homocysteine metabolism [letter| N Engl J Med 1991, 324. 199-200. 
* Steegers-Theunissen RPM, Boers GHJ, Tnjbels JMF. Finkelstein JD, Blom HJ. Thomas CMC. Borm 
GF, Wouters MGAJ, Eskes TKAB Maternal hyperhomocysteinemia a risk factor for neural-tube 
defects Submitted. 
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reduces the NTD recurrence and first occurrence risk significantly (MRC Vitamin 
Study Research Group 1991, Czeizel and Dudas. 1992) 
It is unclear what biochemical mechanism involving folate explains the relation­
ship of this vitamin to the pathogenesis of NTDs Folate, together with vitamin B ] 2 
and vitamin B6, is essential in the metabolism of methionine as described in chapter 
2 5 Homocysteine, and presented in figure 2 8 (Finkelstein 1990) 
Homocysteine levels are decreased during normal pregnancies in healthy women 
(Andersson et al, 1992b) This might be due to either haemodilution or a metabolic 
adaptation to the increased requirement for methionine by the fetus We suggest that 
the occurrence of deficiencies in folate or vitamin Β,
 2 or the presence of any of the 
several genetic defects which impair the metabolism of these vitamins could lead to 
maternal hyperhomocysteinaemia (Kang et al , 1987, Brattstrom et al, 1988a) 
Furthermore, even the mildly elevated concentrations of homocysteine could inter­
fere with closure of the neural tube The preventive effect of the penconceptional 
use of folate is consistent with this hypothesis which we proposed earlier (Steegers-
Theumssen et al, 1991 ) The present study extends that earlier report by measuring 
the response in plasma to methionine loading, the blood levels of the relevant vita­
mins, and the tissue content of cystathionine synthase in a large group of women 
who had given birth to a NTD infant 
MATERIALS AND METHODS 
Study population 
The ethics committee on human experimentation of the University Hospital St 
Radboud, Nijmegen, approved the study protocol We recruited 91 healthy non­
pregnant women, whom we studied after they had given their informed consent 
Exclusion entena included gastrointestinal and endocrine disorders, dietary restric­
tions, and the use, within three months of the study, of contraceptives, vitamin pre­
parations or other pharmacologic agents Group I consisted of forty-one women, 
mean age 35 4 (SD 3 3) years, who had given birth to an infant with a NTD, either a 
meningo(myelo)cele or meningomyeloschisis (n= 23), encephalocele (n= 2) or 
anencephaly (n= 16) The diagnosis of these malformations had been confirmed by 
ultrasound and clinical examination and autopsy The control group (group II) con­
sisted of fifty women without a complicated obstetrical history, mean age 33 3 (SD 
5 3) years 
A standardized, oral methionine loading test was performed in the mid-luteal 
phase of the ovulatory cycle (Boers et al , 1985c, Steegers-Theunissen et al , 
1992a) At that time, we measured the levels of serum and red cell folate, serum 
vitamin B ] 2, and vitamin Bb in whole blood together with routine clinical indices of 
hepatic and renal function In addition, we verified the ovulatory character of the 
menstrual cycle by determining luteal concentrations of 17ß-oestradiol and pro-
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gesterone Subsequently, this was augmented with informalion regarding the first 
day of the next menstrual period 
In those women in which the methionine loading test led to homocysteine levels 
exceeding two standard deviations above the mean concentration of the control 
group, designated as methionine intolerant, a skin biopsy was taken to detei mine the 
activity of cystathionine synthase in the cultured fibroblasts (Boers et al , 1985c) 
Statistical analysis 
Results are expressed as mean (SD) After logarithmic transtormation the ditte 
rences between the groups were evaluated using Students t-test, while Pearsons 
partial correlation coefficients (with the group effect partidled out) were calculated 
to study the relation between the variables Ρ values < 0 05 were considered statisti­
cally significant 
RESULTS 
The mean fasting concentrations of serum and red cell folate, serum vitamin B ] 2 
and of whole-blood vitamin Bft are given in table 6 1 There were no significant dif­
ferences in the vitamin concentrations between the two groups The mean and 
standard deviation of plasma total homocysteine levels in the tasting state and after 
loading are also presented in table 6 1 In the fasting state the mean total homocys­
teine concentration was significantly increased in group I as compared to the con­
centration in group II (P< 0 05) Similarly, the mean aiterload homocysteine con 
centration was significantly higher in group I than in group 11 (P< 0 05) 
Nine out of the 41 patients of group I demonstrated afterload le veis of total homo 
cysteine exceeding the mean plus twice the standard deviation of the correspondent 
controls, ι e , serum concentrations above 32 + 2 χ 8 4= 48 8 μιτιοΙ/L Therefore, 
these women were designated methionine intolerant In these methionine intolerant 
women the mean concentrations of vitamin B ] 2 (264 pmol/L). serum folate (12 
nmol/L), red cell folate (636 nmol/L), and vitamin B 6 (53 0 nmol/L) did not differ 
statistically significant from the control group 
The liver and renal function parameters in all women were within the normal 
range and there was no significant difference in the concentrations of creatinine, 
urea, alkaline phosphatase, AST and ALT between group I and group II 
Pearson s partial coefficients of correlation were calculated between the various 
vitamin levels and the fasting and afterload homocysteine concentrations There 
was a statistically significant negative correlation between serum folate and tasting 
as well as afterload homocysteine levels in group I and group II These correlations 
appeared to be not statistically significantly different between the groups There­
fore, partial correlation coefficients were calculated in both groups taken together, 
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Table 6 I Fasting blood concentrations of vitamins and fasting and afterload levels of total homocys­
teine in women who had given birth to an infant with a NTD (Group I), and in controls (Group 
II): Values are means (SD) 
Total homocysteine (μπιοΙ/L) 
fasting 
afterload* 
Folate (nmoI/L) 
scrum 
red cells 
Vitamin B [ 2 (pmol/L) 
scrum 
Vitamin B 6 (nmol/L) 
whole blood 
Group I 
NTD group 
(n=4l) 
11 
37 
14 
558 
268 
(4 0) 
(13) 
(5) 
(194) 
(100) 
49 4 (14 4) 
Group II 
Controls 
(n=50) 
9.8 
32 
14 
515 
288 
50 1 
(2.6) 
(8.4) 
(4) 
(151) 
(107) 
(12.3) 
Significance 
P<0 05 
P<0 05 
N.S. 
N S 
N.S. 
N S 
' Levels 6-hours after methionine loading (0 I g of methionine per kilogram of body weight). 
being statistically significant respectively, between serum folate and fasting homo­
cysteine r= -0.37 (P< 0.01); and between serum folate and afterload homocysteine 
r= -0.35 (P< 0.01). 
The measured cystathionine synthase activities in the cultured fibroblasts of the 9 
methionine intolerant patients of group I varied between 3.1 and 27.0 nmol.h"1 per 
mg of protein. These data are presented in figure 6.2. The activities were compara­
ble to those of control subjects varying respectively from 2.3 and 18.2 nmol.h"1 per 
mg of protein. In adult obligate heterozygotes the cystathionine synthase activities 
were lower, varying respectively between 0.2 and 2.4 nmol.h"1 per mg of protein. 
DISCUSSION 
Maternal vitamins, especially folate, are important in the pathogenesis and pre­
vention of NTDs (Carter 1974; Rosenblatt 1989; MRC Vitamin Study Research 
Group 1991; Czeizel and Dudas, 1992). It is, however, unclear which precise meta­
bolic mechanism is involved. The present data demonstrate that both fasting and 
afterload homocysteine levels may be significantly elevated in women who had 
given birth to a NTD infant as compared to those in controls. In 9 (22%) mothers of 
a NTD infant hyperhomocysteinaemia after oral methionine loading was esta­
blished. Heterozygosity for homocystinuria due to a deficient cystathionine syn­
thase activity is probably the most frequent cause for such methionine intolerance 
(Boers et al., 1985c). An earlier study showed that the cystathionine synthase acti-
Ίλ 
Cystathionine synthase activity 
(nmol/h'^mg"1) 
АО-i 
30 
2 0 -
10-
< 
Λ 
controls obligate NTD 
heterozygotes 
Figuieft 2 Cystathionine synthase acti\it> measuied in LUltuied libmblasls deteimined in 9 melhio 
nine intolerant women who had h id ι NTD intant 12 commis and 8 obligate huuozygotcs 
tor cystathionine synthase deficiency 
vtty in cultured fibroblasts was decreased in 85% ot obligate heteiozygotes for 
cystathionine synthase deficiency (Boers et al , 1985c) However, the cystathionine 
synthase activities in our 9 hyperhomocysteinaemic women were within the normal 
range Therefore, it is more likely that the mildly elevated homocysteine levels in 
women with NTD ottspring are caused by an impaired remethylation of homocys­
teine to methionine (chapter 2 5 Homocysteine, figure 2 8) In view of the normal 
folate and vitamin B ) 2 blood levels in this gioup as a whole as well as in the subset 
of methionine intolerant women, it is not likely that the decreased availability of 
these vitamins contributes to the hyperhomocysteinaemia Instead, it seems more 
likely that defects in cither the synthesis of 5-methyl THF or in the conversion ot 
vitamin В ] 2 to methylcobalamin could provide an explanation 
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The most frequently described inherited disorder in folate metabolism is 5,10-
methylene THF-reductase deficiency (chapter 2 Review of the literature, figure 2 5, 
no 4. and table 2 7) (Rosenblatt 1989, Kang et al, 1991 ) This enzyme irreversibly 
catalyses the reduction of 5,10-methylene-THF to 5-methyl-THF, which serves as 
the one-caibon donor tor the remethylation of homocysteine to methionine 
Therefore, a deficiency of this enzyme results in a decreased synthesis of 5 methyl-
THF In such patients homocysteine levels in blood and urine are elevated, plasma 
methionine levels are normal or subnormal, and folate levels are low (Rosenblatt 
1989) In all women of group I as well as in the 9 methionine intolerant women the 
serum and red cell folate levels were within the normal range and did not differ sig­
nificantly from the controls The significant role of folate in homocysteine metabo­
lism is supported by the established negative correlation between serum folate 
levels and tasting as well as afterload plasma homocysteine levels in both groups, 
which agrees with the results ot previous studies (Kang et al , 1987, Brattstrom et 
al 1990) The results of Kang et al (1991) are intriguing, finding that 17% of car­
diac patients versus 5% ot the general population suffers from mildly elevated 
homocysteine levels caused by decreased activity of the thermolabile enzyme 5,10-
methylene-THF reductase Theoretically, in our women with a NTD infant, in­
creased homocysteine levels might also be caused by such decreased 5,10- me-
thylene-THF reductase activity 
Inherited defects in vitamin B | 2 metabolism are rare and result in a defective re­
methylation of homocysteine as well The described defects comprise the absorp­
tion and transport ot vitamin B ! 2 , cellular utilization and coenzyme production 
Some delects result in a decreased synthesis of methylcobalamin and this will 
reduce the activity of the en/yme methionine synthase (Surtees and Leonard, 1990) 
Reduced methionine synthase activity leads to pathologically increased homocys­
teine levels hypomethiomnaemia and increased 5-methyl-THF levels (Scott and 
Weir, 1981 ) The trapping ot folate in this form causes a lack of intracellular THF 
This can impair purine and pynmidine metabolism with a resulting limitation in 
DNA synthesis and cellular mitosis In all women of both groups serum total vita­
min В|2 concentrations were within the normal range No significant correlation 
between vitamin B,2 and homocysteine levels could be established However, our 
data do not allow us to exclude the possibility that derangements in cobalamin 
metabolism or defects in methionine synthase cause the hyperhomocysteinaemia in 
mothers of NTD infants 
The teratogenicity of homocysteine in human is unknown In vitro research 
showed that neural-tubes in rat-embryos cultured on methionine deficient cow 
serum were only closing when methionine was supplemented (Coelho et al, 1990) 
These effects could be dependent on the shortage of methionine intracellularly or on 
the availability of the methyl-groups delivered by S-adenosylmethionine, which is 
necessary for DNA and tRNA methylation Because of the reversibility of the con-
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version of S-adenosylhomocysteine to homocysteine, it is possible that hyperhomo-
cysteinaemia results in enhanced S-adenosylhomocysteine concentration (Finkel-
stein 1990) S adenosylhomocysteine is a strong inhibitor ot most reactions in 
which S-adenosylmethiomne acts as the methyl donor Interestingly Aerts et al 
(1991) demonstrated an in vitro embryotoxicity of a high dose of L-homocysteine 
leading to a reduced total morphological score and increased number of maltorma 
tions 
The prevalence ot NTDs has been lound to be ten fold increased in spon­
taneously aborted fetuses (Byrne and Warburton 1986) In the present study nearly 
forty percent of the women of the NTD group had been through one or more spon­
taneous abortions, which is a higher percentage than expected, ι e , about 15 57r in 
the general Dutch population This is in line with the hypothesis that spontaneous 
abortion is a natural process of removing embryos affected with NTDs or other mal 
formations (Byme and Warburton, 1986) Furthermore, preliminary results suggest 
the involvement of hyperhomocysteinaemia in a subset ol women who experienced 
recurrent spontaneous abortion (Steegers-Theunissen et al , 1992b) 
Increased homocysteine levels can be normalized by therapy with a high dose of 
folate, vitamin B ! 2 and vitamin B6 (Boers et al , 1983a, Olszewski et al , 1989, 
Brattstrom et al, 1990) The results ot the MRC Vitamin Study ( 1991 ) and the study 
of Czeizel and Dudas (1992) demonstrate a preventive effect ot maternal pei icon 
ceptional folate treatment on the development of NTDs We relate this beneficial 
effect partially to a preexisting methionine intolerance Future investigations will 
have to be focused on the contribution of maternal and embryonal hyperhomocys 
teinaemia in the pathogenesis of NTDs 
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Chapter 7 
STUDY ON THE PRESENCE OF HOMOCYSTEINE IN 
OVARIAN FOLLICULAR FLUID: POSSIBLE IMPLICATIONS 
FOR NEURAL-TUBE DEFECTS* 
INTRODUCTION 
The pathogenesis of NTDs has not been clarified so far. Decreased periconcep-
lional vitamin levels-a shortage of folate in particular- are likely to be of influence 
(Smithellsetal., 1976; Scott et al., 1990; Steegers-Theunissen et al., 1993a). 
It has been postulated that the risk of having an infant suffering from a NTD is 
increased in methionine intolerant women (Steegers-Theunissen et al., 1991). A 
deficiency of one of the vitamins involved in homocysteine metabolism such as 
folate, vitamin B j 2 and B6 leads to hyperhomocysteinaemia (chapter 2 Review of' 
the literature, figure 2.8) (Brattström et al., 1988a; Stabler et al., 1988; Hall and Chu, 
1990). However, it is unclear what biochemical mechanism involving these vita-
mins explains the relationship with the pathogenesis of NTDs. 
It seems justified to speculate that the composition of ovarian follicular fluid is 
also of importance because the cytoplasm of the oocyte contains yolk granulae 
which provide nutrition during the first few days of development (Biggers 1971 ). 
This study was initiated to determine the presence of homocysteine, methionine 
and the vitamins folate, B ) 2 and B6 in ovarian follicular fluid collected prior to 
ovulation. 
MATERIALS AND METHODS 
Study design 
After informed consent, blood and ovarian follicular fluid samples were obtained 
from 14 Caucasian women enroled in an in vitro fertilization programme. Their 
mean age was 34.2 (SD 4.7) years. The experimental protocol was approved by the 
ethics committee on human experimentation of the University Hospital Si Radboud, 
Nijmegen. Pituitary suppression of all the participating women was performed by 
intranasal administration of the LH-RH analogue Buserelin® (Hoechst AG, 
* Steegers-Theunissen RPM, Steegers EAP, Thomas CMC Hollanders JMG, Copius Peereboom-
Stegeman JHJ, Tnjbels JMF, Eskes TKAB Study on the presence of homocysteine in ovarian follicu-
lar fluid' possible implications for neural-tube defects. Submitted 
78 
Frankfurt/M, Germany) 900 μg daily from day 21 of the previous cycle onwards. 
The subsequent follicular development was stimulated by Humegon® (Organon, 
Oss, The Netherlands), 150 IU daily i.m. from day 3 of the IVF cycle onwards. To 
all patients 10,000 IU of human chorionic gonadotrophin (Pregnyl®, Organon, Oss, 
The Netherlands) was administered i.m. 34-36 hours before follicle puncture. 
Follicular fluid was aspirated by transvaginal puncture, using ultrasound gui­
dance. Samples with macroscopic blood contamination were excluded from analy­
sis. In all patients fluid samples were recovered from more than one follicle and 
pooled before analysis. Non-fasting venous blood samples were taken within 5 
minutes prior to the procedure. In one woman, follicular vitamin B ) 2 and folate con­
centrations could not be measured, due to a logistic imperfection. 
For all assays, ovarian follicular fluid samples were obtained in dry plastic tubes 
of 3 mLand further handling was similar to that of blood. 
Statistical analysis 
Comparison between blood and ovarian follicular fluid concentrations of methio­
nine, homocysteine, folate, vitamin B | 2 and vitamin B 6 was performed by using 
Student's t-test for paired observations. Correlations were evaluated by determina­
tion of the Pearson's coefficient of correlation (r). 
RESULTS 
The concentrations of homocysteine, methionine and the vitamins folate, B ] 2 and 
B 6 in venous blood and preovulatory follicular fluid are presented in table 7.1. 
Detectable amounts of homocysteine and methionine were found in follicular fluid. 
The methionine concentrations appeared to be significantly lower than in corre­
sponding serum samples. 
Table 7 1 The mean (range) concentrations of homocysteine, methionine, folate, vitamin B 1 2 and 
vitamin B,, in blood and ovarian follicular lluid 
Serum Ovarian follicular Ρ 
fluid 
7.4 (3.0, 13) N.S 
16 (10, 26) <0.05 
16 (9 5, 26) N S 
200 (87,390) <0.01 
36 (19, 49) < 0 01 
N S not significant. * whole blood 
Homocysteine (\imo\IL) 
Methionine (μιηοΙ/L) 
Folate (nmol/L) 
Vitamin B|2(pmol/L) 
Vitamin B 6* (nmol/L) 
8 6 
20 
18 
250 
53 
(4 0, 14) 
(10, 35) 
(8.4. 28) 
(78.490) 
(42, 59) 
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Folate concentrations in follicular fluid were not significantly different from 
those in serum Vitamins B | 2 and B6 were present in follicular fluid as well, how­
ever in significantly lower concentrations than in blood 
Serum concentrations of folate, vitamin B 1 2 and homocysteine appeared to be 
significantly correlated with corresponding concentrations in follicular fluid (figu­
res 7 la and 7 lb) However, the concentrations of vitamin B 6 in whole blood and 
methionine in serum were not significantly correlated with those in follicular fluid 
DISCUSSION 
This is the first report to demonstrate the presence of methionine, homocysteine, 
and the vitamins folate, В 1 2 and B 6 in human ovarian follicular fluid The blood con 
centrations of these components were comparable to the values published pre­
viously (Steegers-Theunissen et al, 1991, Steegers-Theunissen et al, 1992a) 
Ovarian follicular fluid is formed by a gradual influx of fluid derived from the 
blood and by compounds synthesized and secreted by the theca interna and granu­
losa cells (Edwards 1974) The established significant correlation between follicu­
lar fluid and serum of homocysteine concentrations suggests that diffusion from the 
ovarian circulation into follicular fluid is the main determinant of its follicular con­
centrations 
The concentration of methionine in preovulatory follicular fluid was slightly but 
significantly lower than in serum No significant correlation between methionine 
levels in blood and follicular fluid could be demonstrated Methionine is converted 
to S adenosylmethionine, which is involved in the methylation of DNA, and there­
by involved in cellular growth and division (Coelho et al, 1987, Coelho and Klein, 
1990, Finkelstein 1990) Thus, follicular methionine may be an important nutrient 
contributing to the growth of granulosa cells and of oocytes 
It has been shown that in a subset of women who had given birth to an infant with 
a NTD, the remethylation of homocysteine to methionine is likely to be disturbed 
due to a decreased activity of one of the involved remethylation enzymes, and/or 
relatively folate or vitamin B l 2 deficiencies leading to raised blood levels of homo­
cysteine (Steegers-Theunissen et al, 1991) Eventually, concomitant methionine 
levels might be decreased as well 
It is largely unknown in what pathogenetic way a metabolic disorder in homocys­
teine metabolism might be related to the prevalence of NTDs We speculate that 
high homocysteine levels or low methionine concentrations, or both, in the direct 
environment of the ovum might be involved as well The composition of follicular 
fluid could have some influence on the contents of yolk granulae of the oocyte 
which provide nutrition during the first days of development (Biggers 1971) In 
vitro research has shown that methionine is an important growth factor, and a shor­
tage of methionine in the culture medium impairs the closure of the neural-tube in 
rat embryos (Coelho et al, 1987, Flynn et al, 1987, Coelho and Klein, 1990) 
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Recently, Aerts et al (1991) demonstrated the in vitro embryotoxicity in rat 
embryos of high doses ot L-homocysteine This toxicity could be reduced by the 
addition of 5-methyl-THF, and of vitamin B ] 2 in particular In view of this finding, 
the presence of folate, vitamin В
 ( 2 and vitamin B6 in follicular fluid, as demonstra­
ted in our study, could also be of significance 
One of the mechanisms by which penconceptional supplementation of folate 
might be effective in reducing the birth prevalence and recurrence risk of infants 
with a NTD could be by influencing the composition ot follicular fluid with respect 
to its folate concentration This hypothesis deserves further investigation (MRC 
Vitamin Study Research Group 1991, Czeizel and Dudas, 1992) 
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Chapter 8 
NEURAL-TUBE DEFECTS AND ELEVATED 
HOMOCYSTEINE LEVELS IN AMNIOTIC FLUID* 
INTRODUCTION 
Decreased levels of folate and vitamin B 1 2 in maternal blood may be related to 
the pathogenesis of NTDs (Smithells et al, 1976, Schorah et al, 1980) Peri-
conceptional folate treatment of the mother is very likely to prevent NTDs (MRC 
Vitamin Study Research Group, 1991, Czeizel and Dudas, 1992) Recently, we 
reported an association between a maternal mild hyperhomocysteinaemia as detec­
ted after methionine loading and not as a cause ot cystathionine synthase deficiency, 
and a history of having offspring with a NTD (Steegers-Theunissen et al, 1991) 
However, it is unclear what biochemical mechanism is involved 
The involvement of 5-methyl-THF, methylcobalamin and pyndoxal phosphate in 
homocysteine metabolism is described in paragraph 2 5 Homocysteine, and shown 
in figure 2 8 Malnutrition or a deranged metabolism of folate or vitamin B | 2 
impairs the remethylation of homocysteine to methionine and results in hyperhomo­
cysteinaemia (Mudd et al, 1989, Finkelstein 1990) The most frequently encounte­
red inherited enzymatic defects in homocysteine metabolism described are defi­
ciencies of the vitamin B6-dependent enzyme cystathionine synthase, and 
5,10-methylene-THF reductase (Mudd et al, 1989, Finkelstein 1990) Noteworthy 
is the recently reported decreased enzyme activity of thermolabile 5,10-methylene-
THF reductase, which results in mild hyperhomocysteinaemia and seems to occur 
in 5% of the general population (Kang et al, 1991) Mildly increased homocysteine 
blood levels can be normalized by treatment with high doses of folate or vitamin B 6 
(Boers et al, 1983a, Brattstrom et al, 1990) 
In the subset of NTDs in which maternal hyperhomocysteinaemia is demonstra­
ted, it would be intriguing to study the homocysteine exposure of the conceptus 
during the period NTDs develop, ι e , the 3rd to 4th week after conception It is not 
feasible to assess the homocysteine concentrations in the yolk sac and neural tissue 
during that early stage of human pregnancy As a putative reflection of that early 
stage, we studied both maternal blood and midtnmester amniotic fluid concentra­
tions of total homocysteine, folate, vitamin B 1 2 and B 6 in women carrying a NTD 
fetus and in women carrying a normal healthy fetus serving as controls 
+
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MATERIALS AND METHODS 
Study populations 
Thirty seven women were recruited and investigated after their written informed 
consent was obtained Exclusion criteria included gastrointestinal and endocrine 
disorders, dietary restrictions, and the use of vitamin preparations or other phar­
macologic agents immediately before or during the current pregnancy Seventeen 
women out of the group carried a fetus suffering from a NTD, ι e , meningo­
myelocele or meningomyeloschisis (n= 12). anencephaly (n= 4), or craniorachis-
chisis (n= 1) (group I) as concluded from α-fetoprotein determinations in amniotic 
fluid and ultrasound examination, and confirmed by the pregnancy outcome The 
control group (group II) consisted of 20 women, in which amniocentesis was perfoi -
med because of high maternal age (between 36 and 40 years) All control women 
gave birth to a healthy child All pregnancies were accurately dated by the last 
menstrual period and first trimester ultrasound investigation The characteristics of 
the studied groups are presented in table 8 1 
Table 8 1 Characteristics of the two groups 
Group I Group II 
NTD women (n= 17) Controls (n=20) 
Age (years) mean (SD) 29 8 ('S 7) 17 7 (1 •))* 
Nulliparous (η) S S 
Gestational age (weeks) mean (SD) 2S 9 (7 7) 15 8 (Ü 8)* 
* P < 0 0 l 
Study design 
Venous blood samples for the determination of plasma total homocysteine, serum 
and red cell folate, serum vitamin B ) 2 and whole blood vitamin B6 as pyndoxal 
phosphate were taken within 10 minutes after amniocentesis Amniotic fluid samp-
les were obtained by routine transabdominal amniocentesis and collected in dry 
tubes of 10 mL All amniotic fluid samples were free from blood contamination All 
samples were assayed within 3 months after collection 
Statistical analysis 
Results are expressed as mean (SD) After logarithmic transformation the diffe-
rences between the groups were evaluated using Welch's t-test, while differences 
between paired observations were validated using Student's t-test Pearson's partial 
correlation coefficients (with the group effect partialed out) were calculated to study 
the relationship between the various variables Ρ values < 0 05 were considered sta­
tistically significant 
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RESULTS 
Amniocentesis was performed at a significantly more advanced gestational age 
in group I as compared to group II, and the women of group II were of significantly 
older maternal age than those of group I (table 8.1). 
The concentrations of total homocysteine, folate, vitamin B ) 2 and vitamin B6 in 
maternal blood and amniotic fluid as found in group I and II are given in table 8.2. 
The mean amniotic fluid concentration of total homocysteine of group I was sig­
nificantly higher than that of group II (P= 0.01). Seven out of this group demonstra­
ted total homocysteine concentrations in amniotic fluid exceeding the mean plus 
twice the standard deviation of the control group, i.e., above 2.3 μπιοΙ/L. The indivi­
dual total homocysteine concentrations in amniotic fluid and plasma in both groups 
are shown in figure 8.1. The mean amniotic fluid concentration of vitamin В12 
tended to be significantly higher in the control group II (P= 0.06). The mean amnio­
tic fluid concentrations of folate and vitamin B6 did not significantly differ between 
the two groups. Similarly, not any of the analytes determined in plasma, or folate in 
red cells, did significantly differ between the two groups. Only in the case of total 
Table 8.2 The mean (SD) amniotic fluid and maternal blood concentrations of total homocysteine and 
vitamins in women carrying a NTD fetus (Group 1). and in women with a healthy fetus 
(Group II) 
Total homocysteine (μπιοΐ/υ 
plasma 
amniotic fluid 
significance within group 
Folate (nmol/L) 
serum 
amniotic fluid 
significance within group 
red cells 
Vitamin B|2(pmol/L) 
serum 
amniotic fluid 
signiticance within group 
Vitamin B 6 (nmol/L) 
whole blood 
amniotic fluid 
significance within group 
Group 1 
NTD women 
(n=17) 
7.3 
2 9 
(3 3) 
(19) 
P<0.01 
14 
11 
N S 
591 
219 
297 
N S . 
38 
20 
N S 
(6) 
(6) 
(260) 
(53) 
(221) 
(12) 
(19) 
Group 11 
Controls 
(n=20) 
7 2 
1 5 
(1.2) 
(0 4) 
P=0.01 
16 
13 
N S . 
657 
234 
471 
N.S. 
38 
14 
N S 
(5) 
(5) 
(159) 
(65) 
(281) 
(9) 
(12) 
Significance 
between 
groups 
N S 
P=0.01 
N.S 
N.S 
N S 
N S . 
P=0.06 
N S 
N S 
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Figure 8.1 Individual plasma and amniotic fluid levels of homocysteine in women carrying a NTD 
fetus (Croup I) and in those carrying a healthy fetus (Group II) 
homocysteine, the mean concentrations determined in plasma were significantly 
higher than those of the corresponding amniotic fluid samples. 
Pearson's partial coefficients of correlation were calculated between homocys­
teine, the various vitamin levels, and maternal and gestational age. Because the cor­
relations appeared to be not significantly different between the groups, correlation 
coefficients were calculated after both groups were pooled. The correlations are 
shown in table 8.3, and figures 8.2a and 8.2b. The total homocysteine concentra­
tions in plasma or amniotic fluid did neither significantly correlate with gestational 
age, nor with maternal age. 
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Table 8 3 Correlation coefficients ol concentrations of total homocysteine both in plasma and amniotic 
Huid with concentrations of lolaie. vitamin B i : . vitamin B6and gestational and maternal age 
Total homocysteine 
plasma 
Folate 
scrum 
red cells 
amniotic Huid 
Vitamin Β ρ 
serum 
amniotic fluid 
Vitamin B(, 
whole blood 
amniotic fluid 
Gestational age 
Maternal age 
N.S - not significant 
Total homocysteine 
plasma 
-0 64 
-0 79 
-0 20 
-0 35 
-0 57 
0 30 
0 04 
-0.12 
-0.14 
-
P < 0 0 1 
P < 0 01 
N S 
Ρ < 0 05 
Ρ < 0 0 1 
N S 
N S 
N S . 
N S 
Total homocysteine 
amniotic fluid 
0 33 
0 47 
-0 45 
0 45 
-0 21 
-0 25 
-0 12 
-0 15 
-0 IS 
-0 01 
Ρ < 0 05 
P < 0 0 1 
P < 0 0 1 
P < 0 0 1 
N S 
N S 
N S 
N S 
N S 
N S 
DISCUSSION 
The present study demonstrates that women carrying a NTD tetus (group I) have 
significantly higher total homocysteine concentrations in their amniotic Huid than 
controls (group II). Plasma total homocysteine levels, however, did not differ signi­
ficantly between both groups. Plasma levels of either group were lower than those 
of non-pregnant women described in chapter 6 (7.2 μιτιοΙ/L in pregnant control 
women versus 9.8 μιτιοΙ/L in non-pregnant control women). This is in accordance 
with other studies (Kang et al.. 1986; Andersson et al., 1992b). This finding associa­
ted with pregnancy might be due to haemodilution, increased remethylation ol 
homocysteine induced by enhanced demands for methionine by the tetus, or to the 
impact of increased concentrations of sex hormones during pregnancy on homocys­
teine metabolism (Boers et al., 1983b; Sleegers-Theunissenetal., 1992a). 
The homocysteine concentrations of both groups studied were significantly 
lower in amniotic fluid than in plasma as has been demonstrated previously in nor­
mal pregnancy outcome (Kang et al., 1986). In the present study a significant 
positive correlation could be established between the homocysteine concentrations 
in the two compartments, i.e., maternal blood and amniotic fluid, and there was no 
significant correlation between vitamins in blood and amniotic fluid (data not 
shown). Therefore, the transplacental transfer of homocysteine may be the most 
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Figure 8 2a Correlations of the concentrations ot total homocysteine in amniotic fluid with gestational 
age, and vitamin В12 in amniotic fluid 
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impoitanl deteiminant of the level of homocysteine in amniotic fluid The report of 
Kuiczynski et al ( 1980) who first described an untreated homocystinunc pregnant 
women withdiamatically increased homocysteine concentration in amniotic fluid is 
in accordance with this obsei vation 
We established the absence ol any significant correlation between total homocys-
teine in plasma or amniotic fluid and gestational age or maternal age (table 8 3 and 
figure 8 2a) Thus, it is unlikely to assume that the significantly higher homocys-
teine levels in amniotic fluid of NTD fetuses as compared to healthy controls are a 
consequence of the higher gestational age at which amniocentesis took place for the 
NTD group, or of the lower maternal age of that group 
Pregnancy is associated with a progressive decline of serum and red cell folate as 
well as seium vitamin B ! 2 concentrations (Shojania 1984) This author states that 
this might be caused by increased fetal demands, blood volume expansion and 
increased urinary excretion as well as changes in maternal folate absorption and 
metabolism In paiticular, changes in vitamin B [ 2 binding contribute to the physio 
logic decieasc of this vitamin in pregnancy (Green et al , 1975, Shojania 1984) 
Also decreased blood levels of vitamin B6 during pregnancy have been described 
(Hamfelt andTuvema 1972 Shane and Contractor 1975) 
Folate or vitamin B l 2 deficiency results in increased homocysteine concentra 
tions in blood and urine (Kang el al , 1987, Brattstrom et al , 1988a, Stabler et a l , 
1988, Hall and Chu. 1990) A significant negative conelation between plasma 
homocysteine and serum as well as red cell folate was observed, which is consistent 
with scveial previous studies (Brattstrom et al , 1990, Kang et al , 1987, Stabler et 
al 1988 Steegers-Theunissen et al 1993b) The mean folate concentrations in 
maternal blood and amniotic Huid of the NTD group were not significantly different 
I rom that of the control group Therefore, the increased homocysteine levels in 
amniotic fluid of the NTD group cannot solely be explained on the base of lower 
lolute conccntiations 
Serum vitamin B ] 2 concentrations were comparable in the NTD group and con-
ti ol women and revealed to be within the normal ranges as given earlier for women 
of comparable age (Sleegers Theunissen et al , 1990, Economides et a l , 1992) In 
both gioups vitamin B P concentrations in amniotic fluid tended to be higher than 
those in serum This is in line with the results of previous studies suggesting that 
there is a transplacental transfer of this vitamin against a concentration gradient 
(Sleegeis-Theunissenet al , 1990, Economides et al , 1992) 
The mean vitamin B,2 concentration in amniotic fluid tended to be significantly 
lower in the NTD group as compared to the control group, which has also been 
demonstrated in earlier studies of Gardiki-Kouidou and Seller (1988) and 
r-conomides et al (1992) in the presence of normal maternal serum vitamin B l 2 
concentrations Lower vitamin B ] 2 levels in amniotic fluid of normal pregnancies in 
women who previously had a NTD infant have been related to increased amniotic 
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fluid transcobalamin levels (Gardiki-Kouidou and Setler 1988 Magnus et al 
1991 ) This phenomenon is thought to be an indication ol a genetic factor in the pre 
disposition to NTDs 
To our knowledge, the presence of vitamin Bb in human amniotic fluid has not 
been demonstrated before The vitamin B 6 levels were lower than in maternal blood 
Its mean concentrations in maternal blood and amniotic fluid ol the NTD gioup 
were similar to the corresponding mean values of the controls No significant coi 
relation between the concentrations ot homocysteine and of ν itamin B 6 in blood and 
amniotic fluid was found 
In summary a significantly higher mean homocysteine concentration was ob 
served in amniotic fluid in the presence of a tetus with a NTD compai ed w ith that ol 
the control group A defect in the remethylation pathway in which lolate and vita­
min B|2 are involved, is suggested The observation in the piesent study is in line 
with the earlier proposed hypothesis (Stcegers Theunissen et al , 1993b) 
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Chapter 9 
HYPERHOMOCYSTEINAEMIA AND RECURRENT 
SPONTANEOUS ABORTION OR 
ABRUPTIO PLACENTAE"1 
INTRODUCTION 
Hibbard (1964) was the first to report an association between spontaneous abor 
tion and abruptio placentae and a maternal folate deficiency due to defective folate 
metabolism outside as well as during pregnancy However, studies on this subject 
are conflicting Homocysteine remethylation into methionine is dependent on both 
folate and vitamin B ) 2 (paragraph 2 5 Homocysteine and figure 2 8) Enzyme defi-
ciencies involved in homocysteine remethylation and folate and vitamin B ] 2 meta-
bolism (and malnutrition and malabsorption of these vitamins) result in hyperhomo-
cysteinaemia (Brattstrom et al , 1988a, Stabler et al , 1988, Ueland and Retsum, 
1989, Hall and Chu. 1990) Classic homocystinuna is an autosomal recessively 
inherited metabolic disorder due to a deficiency of pyndoxine-dependent cystathio-
nine synthase (Mudd et al , 1985, Ueland and Refsum, 1989) This enzyme converts 
homocysteine into cystathionine, and its deficiency results in excess storage of 
homocysteine Untreated homozygous women with classic homocystinuna expe-
rience fetal loss rates of almost 50%, and increased perinatal mortality in the 
offspring of obligate heterozygotes has also been reported (Mudd et al , 1985, Burke 
é ta l , 1992) 
We hypothesized that even moderate hyperhomocysteinaemia might be a risk 
factor for recurrent spontaneous abortion and abruptio placentae Thus, we decided 
to carry out a methionine loading test in non-pregnant women with a history of 
recurrent spontaneous abortion or abruptio placentae, but with no known risk fac-
tors for such events These data were compared with a control group of non-preg-
nant women with a history of normal pregnancies Recurrent abortion was defined 
as two or more successive spontaneous abortions (up to 16 weeks from the begin-
ning of the last menstrual penod) with confirmation by pregnancy test, ultrasound 
scan, or histopalhological examination Blood concentrations of vitamins relevant 
to homocysteine metabolism were also studied 
Steegers Theunissen RPM Boers GHJ Blom HJ Tnjbels JMF Eskes TKAB Hyperhomo 
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MATERIALS AND METHODS 
On the 21st day of the ovulatory cycle we performed a standardized oral methio­
nine loading test in 24 women, mean age 31.8 (SD 4.8) years; fourteen had expe­
rienced recurrent spontaneous abortion and ten had a history of abruptio placentae. 
The controls were fifteen healthy women, mean age 31.4 (SD 4.7) years. All women 
had normal liver and kidney functions and no endocrine or metabolic diseases. 
RESULTS 
Surprisingly, six patients in the study group had concentrations of total homocys­
teine 6 hours after methionine loading more than two standard deviations above the 
mean for controls, i.e., above 38 μπιοΙ/L, (table 9.1). Their fasting homocysteine 
values were also increased, but not significantly. 
Cystathionine synthase activity was measured in cultured fibroblasts of all me­
thionine intolerant patients, and ranged from 1.8-19 nmol.h~* per mg protein (nor­
mal 2.3-18 nmol.rf ' per mg protein), thus excluding heterozygosity for homocys-
tinuria in these patients (Boers et al., 1985c). The cystathionine synthase activities 
are presented in figure 9.1. 
The mean fasting values of folate and especially vitamin B i 2 in serum were lower 
in the hyperhomocysteinaemic women, but not significantly in comparison with 
controls. 
Table 9 I The meni (SD) tasting folate, vitamin В p . vitamin B^. and fasting and atterload serum total 
homocysteine concentiations ot the study group and the control group 
Study group Control group 
Methionine Methionine Methionine 
tolerant intolerant tolerant 
(n=18) (n=6) (n=15) 
Folate (nmol/I ) 
serum 14 (7.1) 9 5 (3.6) 13 (3 7) 
red cells 480 (140) 490 (130) 490 (140) 
Vitamin B ] 2 (pmol/L) 
serum 320 (79) 200 (82) 250 (102) 
Vitamin Br, (nmol/L) 
whole blood 59 (21) 42 (6 2) 49 (8 7) 
Total" homocysteine (pmol/L) 
fasting 6 7 (2 3) 9 2 (2 6) 6 9 (2 4) 
after loading" 27 (5.7) 52 (\5У* * 28 (4.9) 
" Total homocysteine is tiee plus protein-bound homocysteine 
"* Concentrations 6 hours after methionine loading (0 I g/kg of body weight) 
•"*P<0 05 
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Figure 9 I Cystathionine synthase activity measured in cultured fibroblasts in six methionine in­
tolerant women (study group) with a history ot recurrent spontaneous abortion (n= 4) or 
abruptio placentae (n= 2), twelve controls and eight obligate heterozygotes for cystathio­
nine synthase deficiency 
DISCUSSION 
A possible cause for hyperhomocysteinaemia in these 6 women who experienced 
recurrent spontaneous abortion (n= 4) or abruptio placentae (n= 2) may be dimin­
ished homocysteine remethy lation. This may be induced by, for example, decreased 
concentrations of the active form of folate or vitamin B ) 2 or by a deficient activity 
of an enzyme involved in the remethylation process. The frequency of hyperhomo­
cysteinaemia in this group (25%) should prompt further studies on inborn errors of 
folate, vitamin B ] 2, or homocysteine metabolism as pathogenetic mechanism. It 
will also be interesting to relate the effect of the use of periconceptional multivita­
min preparations in subsequent pregnancies in these women to preexisting methio­
nine intolerance. 
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SUMMARY 
PARTI 
In chapter 1 a general introduction is presented and the objectives of the thesis are 
summarized as follows 
1 to study the impact of sex hormones on folate kinetics and homocysteine metabo-
lism (partii), and 
2 to study homocysteine metabolism in cases with abnormal pregnancy outcome, 
in particular with NTDs (part III) 
In chapter 2 the definition and epidemiology of NTDs is given A review is pre 
sented of the observational and intervention studies to demonstrate the beneficial 
effect of maternal multivitamin use, including the use ot folate, on the recurrence 
frequency and birth prevalence of NTDs Folate, vitamin B ] 2 and homocysteine are 
discussed because of their possible role in the pathogenesis of NTDs 
Chapter 3 describes the methodology employed, the relations between the study 
groups, the various analytical methods used, the methionine loading test and the 
procedure of the cystathionine synthase assay 
PART II 
Part II concerns studies related to the impact of sex hormones on folate kinetics 
and homocysteine metabolism 
Since studies suggest an association between a shortage of vitamins, in particular 
that of folate, and the prevalence of NTDs, the importance of vitamin deficiencies in 
the preconceptional period and in early pregnancy has gained increased interest In 
view of the preconceptional status, the study described in chapter 4 was performed 
to determine the consequences of long-term oral sub 50 contraceptive use 
(Marvelon®) in healthy fertile women on blood levels of folate before and after an 
oral test-dose of folic acid monoglutamate and on the excretion of folate in urine 
Serum iron status was measured as well At 210 minutes after orally folic acid 
monoglutamaie loading the median serum folate concentration of the group of oral 
contraceptive users was significantly lower than that ot the control group consisting 
of non-users However, basal folate levels were not lower, but contraceptive users 
showed significantly lower basal serum vitamin B ] 2 concentrations Although this 
data suggests that oral sub-50 contraceptives significantly affect folate kinetics, 
there is no evidence from this study that the folate and vitamin B ( 2 status of long-
term sub-50 contraceptive users is jeopardized by the induction of a deficiency 
Chapter 5 describes the influence of the same oral contraceptive (Marvelon®) on 
fasting serum total homocysteine levels Because the vitamins folate, В
 ! 2 and B 6 are 
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involved in homocysteine metabolism, their blood concentrations were studied as 
well The median serum homocysteine concentration of contraceptive users was 
significantly higher than that of controls during the low-hormonal phase of their pill 
or menstrual cycle (respectively on the 3rd pillfree day or the 3rd menstrual day) and 
comparable with concentrations determined in heterozygotes for homocystinuna 
Homocysteine concentrations in the high-hormonal phase appeared not to be signi­
ficantly different between both groups (i.e , the 14th pill day and 21st day ot the 
menstrual cycle) No significant differences in levels of folate and vitamin В,
 2 were 
found between both groups in the low- and high-hormonal phase Blood concentra­
tions of vitamin B 6 were significantly lower in oral contraceptive users, both in the 
low- and the high-hormonal phase Within both groups the mean vitamin B ] 2 con­
centrations were significantly lower on the high- hormonal phase ot the pill and 
menstrual cycle The serum homocysteine concentrations in oral contraceptive 
users in the high-hormonal phase of the cycle were significantly lower compared 
with those on the low-hormonal day This data suggests that cyclically recurrent 
periods of mildly increased homocysteine levels do occur during oral sub-50 con­
traceptive use in normal healthy women and might be important in the occurrence of 
future vascular complications 
PART III 
Part III describes studies on homocysteine metabolism in cases with abnormal 
obstetrical outcome, in particular NTDs 
In chapter 6 homocysteine metabolism and the concentrations of the involved 
vitamins were studied in non-pregnant multiparae who had had an infant with a 
NTD, and in healthy non-pregnant cyclic women serving as controls Homocysteine 
metabolism was studied by performing a standardized oral methionine loading test 
The mean total homocysteine concentrations in the fasting state and after methio­
nine loading were significantly higher in women with an NTD infant In 22% of this 
group the homocysteine levels after methionine loading were higher than two stan­
dard deviations above the mean level of the control group These methionine intole­
rant women demonstrated a normal activity of the enzyme cystathionine synthase 
Therefore, these findings rather suggest a disorder in the remethylation of homocys­
teine to methionine due to an acquired, ι e , nutritional, or inherited derangement of 
folate or vitamin B ) 2 metabolism 
Based on these results we hypothesized that high homocysteine or low methio­
nine concentrations, or both might be involved in the pathogenesis ot a subset of 
NTDs In order to investigate whether there was also a lack of vitamins in the inti­
mate environment of the oocyte, we studied in chapter 7 the presence ot homocys­
teine, methionine and the vitamins folate, B ] 2 and B 6 in ovarian follicular fluid 
obtained from women participating in an m vitro fertilization programme De­
tectable amounts of homocysteine and methionine were found in ovarian follicular 
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fluid Homocysteine concentrations were similar to those in plasma and methionine 
concentrations proved to be slightly, but significantly lower than in corresponding 
blood samples Concentrations of the vitamins B ] 2 and B 6 were significantly lower 
in ovarian follicular fluid than in blood, whereas folate concentrations were not sig­
nificantly different from those in scrum A significant correlation between corre­
sponding serum and ovarian follicular fluid concentrations of homocysteine, folate 
and vitamin В
 ] 2 could be established 
This data supports the hypothesis that the oocyte might be exposed to high homo­
cysteine and low vitamin concentrations, which might be important in the pathoge­
nesis of a subset of NTDs 
In the subgroup of NTDs in which maternal hyperhomocysteinaemia is demon­
strated, it would be intriguing to study the homocysteine exposure of the conceptus 
during the period in which NTDs develop However, it is not feasible to assess the 
homocysteine concentrations in the yolk sac and neural tissue in the human during 
the very early stage of pregnancy, ι e , the 3rd to 4th week after conception As a 
putative reflection ofthat early stage, both maternal blood and midtrimesler amnio­
tic fluid concentrations of total homocysteine and relevant vitamins were studied in 
women carrying a NTD fetus (chapter 8) These results were compared with a con­
trol group of women carrying a healthy fetus without an increased NTD risk The 
homocysteine concentrations in amniotic fluids of the NTD pregnancies were signi­
ficantly higher as compared to those of controls Although the vitamin В
 ) 2 concen­
trations in amniotic fluid tended to be lower in women carrying a fetus with a NTD, 
the concentrations of vitamin B p in maternal blood were not significantly different 
Folate and vitamin B 6 concentrations in amniotic fluid and blood were not signifi­
cantly different between the groups The result of this study is in line with the pre­
vious hypothesis of chapter 6, ι e , that at least a subset of NTDs could reside in a 
derangement of maternal homocysteine metabolism 
The precise mechanism in the pathogenesis of recurrent spontaneous abortion 
and abruptio placentae is often unclear To investigate a possible metabolic mecha­
nism, homocysteine metabolism was investigated in a small study described in 
chapter 9 In 25% of the non-pregnant women, ι e , in 6 out of 24, who had experien­
ced recurrent spontaneous abortions (n= 4) or abruptio placentae (n= 2), a distur­
bance of homocysteine metabolism could be determined, which was not due to a 
decreased cystathionine synthase activity Therefore, these preliminary findings 
suggest that a subset of these women demonstrates a disorder in the remethylation of 
homocysteine to methionine due to an acquired, ι e , nutritional, or inherited de­
rangement of folate or vitamin B ! 2 metabolism 
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CONCLUSIONS 
1. A derangement of maternal homocysteine metabolism leading to hyperhomocys-
teinaemia after methionine loading is detectable in 22% of women who gave 
birth to a child with a NTD; 
2. A disorder in the remethylation of homocysteine to methionine due to an acqui-
red, i.e., nutritional, or inherited derangement of folate or vitamin B ] 2 metabo-
lism is suggested to be the cause of maternal methionine intolerance; 
3. The reported preventive effect of periconceptional folic acid supplementation on 
the prevalence of NTDs in human could, at least partially, reside in the normali-
zation of a preexisting maternal methionine intolerance; 
4. Long-term oral sub-50 contraceptive use affects folate kinetics without inducing 
a folate deficiency; Furthermore, the use of these sex steroids seems to induce 
cyclically recurrent periods of mildly increased homocysteine levels, and there-
fore, they might be important in the occurrence of future vascular complications. 
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SAMENVATTING 
DEEL I 
In hoofdstuk 1 wordt een algemene introductie gegeven en worden de doelstel-
lingen van dit proefschrift als volgt samengevat: 
1. het bestuderen van de invloed van geslachtshormonen op de foliumzuurkinetiek 
en op het homocysteinemetabolisme (deel II), en 
2. het bestuderen van het homocysteinemetabolisme in relatie tot een afwijkende 
zwangerschapsuitkomst, in het bijzonder neurale-buisdefecten (deel III). 
In hoofdstuk 1 wordt de definitie en epidemiologie van neurale-buisdefecten uit-
eengezet. Hierna volgt een literatuuroverzicht betreffende observationele en inter-
ventiestudies naarde relatie tussen het maternale foliumzuurgebruik en de preventie 
van neurale-buisdefecten. Foliumzuur, vitamine B ) 2 en homocysteine worden be-
sproken in verband met een mogelijke rol die deze stoffen spelen in de Pathogenese 
van neurale-buisdefecten. 
In hoofdstuk 3 wordt een overzicht gegeven van de toegepaste methodieken. Het 
betreft de samenhang tussen de studiegroepen en de beschrijving van de laborato-
riumbepalingen, de belastingstest met methionine en de bepaling van de enzym-
activiteit van het cystathionine synthase. 
DEEL II 
In deel 2 van dit proefschrift wordt de invloed van geslachtshormonen op de fo-
liumzuurkinetiek en het homocysteinemetabolisme beschreven. 
Omdat talrijke studies een associatie suggereren tussen vitaminedeficiënties, in 
het bijzonder van foliumzuur, en de prevalentie van neurale-buisdefecten, is er een 
toenemende belangstelling voor de invloed van een tekort aan vitaminen in de peri-
conceptionele periode en tijdens de jonge zwangerschap. Gezien het belang van de 
preconceptionele status beschrijft hoofdstuk 4 een studie omtrent het effect van 
langdurig oraal sub-50 contraceptivum gebruik (Marvelon®) door gezonde fertiele 
vrouwen op de foliumzuurconcentraties in het bloed vóór en na toediening van een 
orale dosis foliumzuur monoglutamaat. De uitgescheiden hoeveelheid foliumzuur 
in de urine werd bepaald, evenals de ijzerstatus in het serum. De basale foliumzuur-
spiegels waren niet verschillend tussen beide groepen, terwijl 210 minuten na orale 
inname van de dosis foliumzuur monoglutamaat significant lagere foliumzuurcon-
centraties in het bloed werden vastgesteld bij contraceptivagebruiksters vergeleken 
met controles. De contraceptivagebruiksters vertoonden wel significant lagere vita-
mine В|2 concentraties. Deze gegevens suggereren dat langdurig gebruik van een 
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oraal sub-50 contraceptivum de fohumzuurkinetiek significant beïnvloedt Deze 
studie toont echter niet aan dat de foliumzuur en vitamine B ] 2 status van vrouwen 
tijdens of kort na het staken van langdurig oraal sub-50 contraceptiva gebruik 
gevaar loopt 
In hoofdstuk 5 wordt de invloed beschreven van het orale contraceptivum 
Marvelon® op de nuchtere totaal-homocysteineconcentratic in het serum Omdat de 
vitaminen foliumzuur, B ! 2 en Β
ή
 nauw betrokken zijn bij het metabolisme van 
homocysteine werden de bloedconcentraties van deze vitaminen eveneens bestu­
deerd De mediane homocysteineconcentratie in het serum van contraceptiva-
gebruiksters was significant hoger dan van de controlegroep gedurende de laag-hor-
monale fase, d w z op de 3e pilvnje dag versus de 3e dag van de menstruele cyclus 
De gemeten concentraties waren vergelijkbaar met de waarden bij heterozygoten 
voor homocystinune De homocysteineconcentraties in de hoog-hormonale fase 
waren niet significant verschillend tussen beide groepen (d w.z tussen de 14e pil 
dag en de 21e dag in de menstruele cyclus). In de spiegels van de vitaminen folium­
zuur en В|2 werden geen significante verschillen vastgesteld tussen beide groepen 
in zowel de laag- als hoog-hormonale fase In de laag- en hoog-hormonale fase 
waren de mediane concentraties van vitamine B 6 in het bloed significant lager bij de 
groep van contraceptivagebruikslers Binnen beide groepen was de mediane vita­
mine B 1 2 concentratie significant lager in de hoog-hormonale fase vergeleken met 
de laag-hormonale fase van respectievelijk de pil- en menstruele cyclus De homo-
cysteineconcentraties van contraceptivagebruiksters waren significant lager in de 
hoog-hormonale fase van de cyclus vergeleken met de laag hormonale dag Deze 
resultaten suggereren de aanwezigheid van cyclische perioden van mild verhoogde 
homocysteinespiegels bij gezonde vrouwen die een oraal sub-50 contraceptivum 
gebruiken Deze bevindingen zijn wellicht van belang bij het toekomstig optreden 
van vasculaire complicaties 
DEEL III 
In deel III worden studies beschreven waarin het homocysteinemetabolisme 
werd bestudeerd bij vrouwen met een afwijkende zwangerschapsuitkomst, in het 
bijzonderde neurale-buisdefecten 
In hoofdstuk 6 wordt het homocysteinemetabolisme en de concentraties van de 
betrokken vitaminen bestudeerd bij met-zwangere multiparae die eerder een kind 
hebben gekregen met een neurale-buisdefect, en bij met-zwangere controles met 
een ovulatoire cyclus Het homocysteinemetabohsme werd bestudeerd met behulp 
van een gestandaardiseerde orale belastingstest met methionine De gemiddelde 
totaal-homocysteineconcentratie. gemeten in de nuchtere situatie en na belasting 
met methionine was significant hoger bij moeders van een kind met een neurale-
buisdefect Bij 22% van deze groep vrouwen waren de homocysteinespiegels na 
1СЛ 
belasting met methionine hogei dan de som van het gemiddelde plus tweemaal de 
standaarddev ìatie van de controlegroep De activiteit ν an het cv stathionine synthase 
in deze subgroep lag binnen de normale grenzen Deze resultaten suggeieien dat er 
mogelijk sprake is van een stoornis in de remethylering van homocysteine naai me­
thionine, die veroorzaakt zou kunnen worden door een veiworven stoornis (bijvooi-
becld voedingsdeticienties) ofeifehjke afwijking in het metabolisme van folium­
zuur ot vitamine B|2 
Vanuit deze achtergrond werd de hypothese opgesteld dat hoge homocysteine- of 
lage methiomneconcentraties, of beide betrokken zouden kunnen zijn in de Patho­
genese vaneen subgroep van neurale-buisdefecten Ter beantwooiding van de vraag 
of er ook een tekort aan ν ïtaminen in de directe omgev ing ν an de oocyt zou kunnen 
optreden, wordt in hoofdstuk 7 de aanwezigheid van homocysteine, methionine en 
de vitaminen foliumzuur, B ! 2 e n B 6 inde tollikelvloeistof van het ovarium beschie 
ven De benodigde specimen werden verzameld bi| vrouwen die deelnamen aan een 
in vitro fertilisatie programma Detecteerbare hoeveelheden homocysteine en me 
thiomne werden gevonden in de folhkelvloeistof De homocysteineconcentralies 
waren vergelijkbaar met de gemeten waarden in plasma, terwijl de methioninecon 
centraties significant, zij het in geringe mate, lager bleken te zijn dan de concenti a 
ties in de corresponde! ende bloedmonsters De concentraties van de vitaminen B 1 2 
en В 6 waren significant lager in de tolhkelvloeistot dan in het bloed terwijl de 
fohumzuurconcentraties niet significant verschilden van de waarden in het serum 
Een significante correlatie tussen de corresponderende serum- en lollikelvloeistof 
concentraties van het homocysteine, het foliumzuui en vitamine B ) 2 kon worden 
vastgesteld 
Deze resultaten ondersteunen de hypothese dat oocyten blootgesteld zouden kun 
nen worden aan hoge homocysteine- en lage vitamine concentraties Dit zou van 
belang kunnen zijn in de Pathogenese van een subgroep van neuiale buisdefecten 
In de groep van neurale-buisdefecten waarin een mateinale hyperhomocvs-
teinaemie werd aangetoond is het interessant de homocysteineblootstelling van de 
conceptus nader te bestuderen gedurende de periode waarin neurale-buisdefecten 
zich ontwikkelen Omdat het niet realiseerbaar is homocysteineconcentraties te 
meten in de humane dooicrzak en het neurale weefsel gedurende dit vroege stadium 
in de zwangerschap, de "Ïe tot 4e week na de conceptie, werd gekozen voor een 
andere opzet In het tweede trimester van de zwangerschap werden concentraties 
van het totaal homocysteine en relevante vitaminen bestudeerd in het maternale 
bloed en vruchtwater van vrouwen die zwanger waren van een foetus met een neur 
ale-buisdefect (hoofdstuk 8) De resultaten werden vergeleken met een controle 
groep bestaande uit vrouwen die zwanger waren van een gezonde foetus en die geen 
verhoogd risico hadden op een kind met een neurale-buisdefect De homocysteine-
concentraties in het vruchtwater van de zwangerschappen waarbij een foetus met 
een neurale-buisdefect aanwezig was, waren significant hoger dan in de controle-
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groep Ofschoon de vitamine B 1 2 concentraties in het vruchtwater lager bleken te 
zijn bij vrouwen die zwanger waren van een foetus met een neurale buisdefect, 
waren de concentraties van vitamine В 1 2 in het maternale bloed niet significant ver­
schillend Foliumzuur en vitamine B6-concentraties in vruchtwater en bloed waren 
niet significant verschillend tussen de beide groepen De resultaten uit deze studie 
ondersteunen de voorgaande hypothese uit hoofdstuk 6, namelijk dat er bij een sub­
groep van neurale-buisdefecten mogelijk sprake is van een stoornis in het maternale 
homocysteine metabolisme 
De Pathogenese van de herhaalde spontane abortus en de solutio placentae is 
vaak onduidelijk Ter bestudering van een mogelijk metabole oorzaak werd het 
homocysteinemetabolisme bestudeerd bij een kleine studiegroep beschreven in 
hoofdstuk 9 Bij 25% van de met-zwangere vrouwen (6 van de 24) die een herhaalde 
spontane abortus of solutio placentae hadden doorgemaakt, kon een stoornis in het 
homocysteinemetabolisme worden vastgesteld, die niet veroorzaakt werd dooreen 
verlaagde activiteit van het cystathionine synthase 
Deze eerste bevindingen suggereren dat in een subgroep van deze vrouwen een 
stoornis in de remethylenng van de metaboliet homocysteine naar methionine aan 
wezig is, die veroorzaakt wordt door een verworven stoornis (bijvoorbeeld een voe-
dingsdeficientie) of erfelijke afwijking in het foliumzuur of vitamine B 1 2 metabo­
lisme 
CONCLUSIES 
1 Een stoornis in het homocysteine metabolisme resulterend in een hyperhomocys-
teinaemie na belasting met methionine is vast te stellen bij 22% van de moeders 
van een kind met een neurale-buisdefect, 
2 Het vermoeden bestaat dat de maternale hyperhomocysteinaemie wordt veroor­
zaakt door een stoornis in de remethylenng van het homocysteine naar het me­
thionine tengevolge van een verworven stoornis (bijvoorbeeld voedingdeficien-
ties) of erfelijke afwijking in het foliumzuur of vitamine B ) 2 metabolisme, 
3 Het gerapporteerde preventieve effect van penconceptionele toliumzuursupple-
tie op de geboorteprevalentie van neurale-buisdefecten bij de mens zou gedeelte­
lijk kunnen worden toegeschreven aan de normalisering van een pre existente 
maternale methionineintolerantie, 
4 Langdurig gebruik van een oraal sub-50 contraceptivum beïnvloedt de fohum-
zuurkinetiek doch lijkt geen fohumzuurdeficientie te induceren Daarnaast lijkt 
het gebruik van geslachtshormonen cyclisch herhaalde perioden van mild ver-
hoogde homocysteinespiegels te veroorzaken Om deze reden zou het gebruik 
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van orale contraceptiva van invloed kunnen zijn bij het optreden van toekomstige 
vasculaire complicaties. 
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Willems) bepaalden vele bloedmonsters 
De keuzevakstudenten Paul de Jong, Carolien Swanink en Els van der Molen, 
voor hun praktische bijdrage aan studies beschreven in dit proefschrift 
- Gerda Theunissen, Yvonne Lawson en Riet Fhervoet voor hun gewaardeerde 
secretariële ondersteuning 
- De teams van de 'Prenatale Diagnostiek' en de 'In vitro fertilisatie' binnen ons 
instituut voor het aanleveren van vruchtwater, bloed en folhkelvloeistof 
- Stafleden, arts-assistenten en verloskundigen voor hun betrokkenheid bij het 
onder/oek 
- Peter Janssen van de bibliotheek van de Praekhniek, Cees Nicolasen en Yvonne 
Dethmers van de tekenkamer, en de medewerkers van de medische totografie 
- Alle patiënten en vrijwilligsters, zonder wier bereidwillige medewerking dit 
onder/ock onmogelijk zou zijn geweest 
- Met name ook mijn ouders, die alles in het werk stelden teneinde hun kinderen 
alle kansen te bieden, voor hun zorgzaamheid en continue steun 
- Ene, echtgenoot en "derde promotor" Veel eer komt jou toe Je onvoorwaarde-
lijke vertrouwen en begrip was en is zo onmisbaar en tegelijk ook zo bijzonder 
Lieve Cathelijne en Koen, voor het genot jullie gezond te zien opgroeien, en de 
gezellige uurt|es die we doorbrachten op mijn kamer om samen nog 'even te wer-
ken' 
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CURRICULUM VITAE 
De schrijfster van dit proefschrift werd op 14 mei I960 geboren Na het voor 
bereidend wetenschappelijk onderwijs te Nijmegen werd in 1979 de studie Genees 
kunde aangevangen aan de Katholieke Universiteit te Nijmegen Het arts examen 
werd in 1986 afgelegd Als student-assistent was zij van 1982 tot 1981 verbonden 
aan het laboratorium voor Anatomie en Embryologie (destijds hoofd Prof Dr H J 
Lammers) van de Katholieke Universiteit Met het doel medisch studenten een 
zwangerschap en bevalling mee te laten maken organiseerde zij in 1981-1984 het 
project 'Longitudinale Zwangerschapsbegeleiding' In 1984 werd gedurende 4 
maanden de wetenschappelijke stage "Obstetrical policy during labour and perina-
tal results" verricht binnen het instituut voor Obstelne en Gynaecologie (hoold 
Prol Dr E M Symonds) van het Queen's Medical Centre, University of Notting-
ham in Engeland Van 1986 tot heden is zij als wetenschappelijk medewerker werk 
zaam binnen het instituut voor Obstetne en Gynaecologie van het Academisch zie 
kenhuis St Radboud te Nijmegen Van 1986 tot 1990 werd het landelijk onderzoek 
"Epilepsie, zwangerschap en aangeboren afwijkingen" verricht Vanaf 1990 tol 
heden werden de in dit proefschrift beschreven studies verricht Zij is getrouwd mei 
Dr Ene Steegersen moeder vanCathelijne (6 jaar) en Koen(ljaai) 

STELLINGEN 
behorende bij het proefschrift 
"Homocysteine, vitamins and neural-tube defects" 
I 
Bij 22%· van de vrouwen die een kind hebben gekregen met een neurale-buisdefect 
blijkt er sprake te zijn van een milde hyperhomocysteinaemie in de nuchtere situatie 
en na orale belasting met methionine 
(dit proef~schi ι ft) 
II 
Het preventieve effect van matemale foliumzuursuppletie gedurende de penconcep-
tionele periode op de prevalentie van neurale-buisderecten bij de mens, zou gedeelte­
lijk toegeschreven kunnen worden aan de normalisering van een preexistente mater-
nale hyperhomocysteinaemie 
(dit proeficlvift) 
III 
Het bepalen van de homocysteineconcentratie in het serum lijkt een betrouwbare maat 
te zijn voor de foliumzuur en vitamine В ]
 2 status 
(Hall CA Chu RC Eui J Haematol 1990 45 143 149 ) 
IV 
"We ought not to set congenital malformations aside with idle thoughts or idle words 
about 'curiosities' or 'chances' Not one of them is without meaning, not one that might 
not become the beginning of excellent knowledge, if only we could answer the 
question why is it rare or being rare, why did it in this instance happen9" 
(PaçetJ Lancet 1882 ) 
V 
Uit onderzoek blijkt dat foliumzuursuppletie van zinkdeficiente ratten het aantal 
neurale-buisdefecten doet toenemen (Quinn et al Br J Nutr 1990,64 233-243) Het 
onderzoek naar de foliumzuur-zink-relatie bij de mens is dan ook essentieel gezien het 
voorschrijven van (extra) foliumzuur aan fertiele vrouwen met zwangerschapswens 
VI 
De Katholieke Universiteit moet zich "meer dan door een naam" profileren door 
vooral identiteitsgevoelige onderwerpen te bestuderen, daar inhoud aan te geven en 
hierover in wetenschappelijke tijdschriften te publiceren 
VII 
De ontwikkeling van het menselijk leven verloopt van de conceptie tot de dood 
De wetenschap heeft weliswaar fasen aangebracht ter bestudering van het menselijk 
leven, echter deze fasen zijn artificieel en men kan uit de ontwikkelingsbiologie dan 
ook geen waarde oordeel zoals toenemende beschermwaardigheid destilleren 
VIII 
De ambtelijke tendens om over steeds meer persoonsgegevens te willen beschikken 
staat in schril contrast met de ontoereikendheid waarmee congenitale afwijkingen in 
dit land worden geregistreerd 
IX 
Vrouwen met epilepsie dienen in de overweging of ze zwanger willen worden het feit 
te betrekken dat er een positieve relatie lijkt te bestaan tussen de duur van de epilepsie 
en het antiepileptica gebruik enerzijds en het afwijkend verloop van de zwangerschap 
anderzijds (spontane miskramen en aangeboren afwijkingen) 
(Steegers Theumssen et al [abstract] Seizuie 1992,1 Supp A 6/12 ) 
X 
Het adviseren van een hoge dosis foliumzuur aan epileptische vrouwen met zwanger-
schapswens wordt vooralsnog onvoldoende wetenschappelijk ondersteund 
XI 
Zinkdeficiente mensen lopen een verhoogd risico om 'effectief besmet te raken door 
HIV's en andere (retro)virussen waaruit zich dan vervolgens ook gemakkelijk een 
ziekte als AIDS in z'n volle omvang kan gaan ontwikkelen 
(SpnenmaJE Oithomoleculair 1993 2 72-79 ) 
XII 
Een apart spreekuur voor preconceptionele zorg dient complementair te zijn aan de 
erfelijkheidsadvisenng 
XIII 
Het succes van een werkende moeder is rechtevenredig met de kwaliteit van de 
kinderopvang thuis 
XIV 
Dressuur is de basis voor het bedrijven van paardensport, dit is vergelijkbaar met de 
betekenis van de wetenschap voor het grensverleggend medisch handelen 
Nijmegen, 7 september 1993 R Ρ M Steegers-Theunissen 


